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Capsaicin is the pungent compound in chili peppers. Capsaicin causes dose-
dependent respiratory and cardiovascular failure by all routes. The capsaicin receptor, 
TRPV1, is a ligand-gated calcium channel. TRPV1 is expressed in sensory neurons and 
various non-neuronal cells in the lung, including epithelial cells of the conducting 
airways and alveoli. In human lung bronchial epithelial and alveolar cells, plasma 
membrane and endoplasmic reticulum (ER) populations of TRPV1 differentially 
influence cytokine gene expression and cell death via changes in cytosolic calcium 
concentrations, but a precise mechanism for TRPV1-mediated cytotoxicity was 
previously undefined.  This project investigated how prototypical and endogenous 
TRPV1 agonists damage lung cells. Structure activity relationships between cell death 
and capsaicinoids with varied potency, and the role of TRPV1 in lung injury due to 
unfettered systemic inflammation were studied. In vitro assays for cell viability and 
calcium flux, quantitative analysis of gene expression patterns, and mutagenesis of 
regulatory gene products demonstrated that TRPV1 activation caused extensive ER 
calcium efflux, ER stress, and cell death. A series of capsaicinoid analogues were 
developed to determine the specificity of TRPV1 activation and ER stress as a common 
mechanism of toxicity in various human lung cell types. Structural modifications to the 
vanilloid ring drastically reduced the ability of capsaicinoids to activate TRPV1 and, 
accordingly, both ER stress and cytotoxicity were attenuated. Molecular modeling of 
  iv 
analogue-TRPV1 binding corroborated these results and highlighted key structural 
features of capsaicin required for TRPV1 activation and cytotoxicity. Endogenous 
TRPV1 agonists have recently been implicated as pneumotoxicants during systemic 
inflammation. Treatment of mice i.p. with lipopolysaccharides (LPS) promoted systemic 
inflammation and lung injury. TRPV1 knockout mice and mice co-treated with the 
TRPV1 antagonist LJO-328 were protected from lung injury and evidence of an ER 
stress response was diminished. The endovanilloid anandamide induced ER stress and 
lung cell death in vitro, but these effects were not blocked by TRPV1 antagonist co-
treatment, suggesting that other endovanilloids may cause ER stress and lung injury in 
mice. The results of this project provide a concerted mechanism of TRPV1-mediated 
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 The ability to sense and dynamically interact with the ever-changing environment 
requires an advanced sensory system. For all organisms, even the most rudimentary 
senses of touch, taste, sight, smell, and sound are vital. Understanding of the mechanisms 
underlying sensory perception has steadily increased, yet much remains to be discovered 
about specific receptors that differentially detect sensory stimuli. Investigation continues 
as to the physiological importance of receptor-mediated events in different cell types, the 
potential role for neuronal receptors to act as nontraditional ‘sensors’ of environmental 
variables in non-neuronal cells, and how receptor protein responses (e.g., ion flux) are 
coupled with subcellular signaling pathways and higher systemic functions.  
 Evolution drives the development and refinement of complex systems to sense 
and to compensate for noxious, irritating, and potentially harmful stimuli.  Progressive 
development of the sensory system allows humans and other organisms to differentiate 
between pleasant and detrimental experiences. Consider the warmth of sunshine versus 
the painful burn of a flame, the gentle cooling sensations from a sea breeze versus icy 
arctic winds, and the ability to sense pleasant food aromas versus a potentially lethal gas 
exposure.  The ability to perceive ‘negative’ sensory experiences affords protection 
because the nervous system gathers sensory input and coordinates appropriate responses 
to minimize harm.  Several members of the Transient Receptor Potential (TRP) family of 
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ion channels have been identified as critical sensors of harmful environmental conditions. 
Select TRP channels in neurons elicit reflex responses and avoidance (nocifensive) 
behavior, activate the innate immune system to increase host defenses against injury, and 
initiate compensatory repair processes to mitigate injury and promote a return to 
homeostasis.  Promotion of homeostasis is also associated with activation of TRP 
channels in non-neuronal cells. 
 This review will briefly describe salient traits of different TRP channels, with 
emphasis on TRP channels expressed in the respiratory tract, followed by a discussion of 
select TRPs as mediators of normal and pathological processes in the lung. Four areas of 
research will be highlighted: 1) basic characteristics of TRP channels; 2) endogenous 
agonists of TRPV1 (endovanilloids) and the role of TRPV1 as a mediator of lung injury 
due to severe systemic inflammation; 3) the role of TRP channels, particularly TRPC1, 
TRPC4 and TRPV4, in regulating vascular endothelial barrier integrity with respect to 
changes in vascular pressure, airway distention, and systemic inflammatory conditions; 
and 4) the potential role of TRP channels as sensors for inhaled ambient particulate 
pollutants and mediators of pulmonary inflammation and injury associated with these 
ubiquitous environmental toxicants. 
 
 
1.1 TRP Family of Ion Channels 
 The TRP family of ion channels is comprised of 28 gene products in humans, 
divided into six different subfamilies:  TRPA (ankyrin), TRPC (canonical), TRPM 
(melastatin), TRPML (mucolipin), TRPP (polycystin), and TRPV (vanilloid) (1-5). Two 
nonmammalian subfamilies, TRPN (C. elegans, zebrafish and Drosophila) and TRPY 
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(yeast) also exist, but will not be covered in this review.  TRP subfamilies are grouped 
based on similarities in genetic/amino acid sequence and associated structure and 
function (6). Several comprehensive reviews of TRP channels have been recently 
published, with additional information that is not included in the scope of this review (2-
5, 7, 8). 
All TRP channels have six trans-membrane domains, a pore-loop region between 
trans-membrane domains 5 and 6, and are generally permeable to cations. TRP channels 
are expressed in all tissues and cell types in mammals, and generally function as 
environmental sensors and signal integrators to help organisms dynamically sense and 
appropriately respond to their environments. TRP channels function as tetramers, where 
four channel subunits assemble to form a central pore comprised of the pore-loop regions 
of the four subunits.  Additionally, some TRP channels reportedly form heterotetramers 
composed of different members of the same (and possibly other) subfamilies to produce 
functionally distinct complexes. For example, TRPC1 and TRPC3 form heterotetramers 
with functions that may be distinct from the function of the channel alone, although this 
is still an area of much research and debate (9).  Heterotetramer formation further 
expands the potential capabilities of these channels as selective sensors of diverse 
conditions and specific mediators of distinct compensatory processes.  
Although they are structurally similar, there are many differences between TRP 
channels. Individual TRP channels are highly diverse in their intracellular N- and C-
terminal domains, where significant regulation of TRP channel function occurs via 
protein-protein interactions and posttranslational modifications. TRP channels also vary 
in relative subcellular location, expression level in different cell and tissue types, and in 
! 4 
mRNA processing and translated protein composition. TRP channels have distinct 
agonist and antagonist selectivity, relative cation permeability, modes of action, and 
sensory and cellular functions.  
 TRP channels were first identified in Drosophila for their role in retinal signal 
transduction (10). Although differences exist between organisms, cell types, and organ 
systems, TRP channels are highly conserved across species and channel homologs tend to 
function in similar ways. TRP channels contribute to sensory functions including vision 
(Drosophila TRP), the detection of warm, cool, and cold temperatures (TRPV1-4, 
TRPA1 and TRPM8), taste (TRPM5 and others activated by spice components), 
osmolarity and membrane tension (TRPM3, TRPV4), and hearing (TRPV4) (1-3, 5, 11-
15).  
1.1.1 TRPA Subfamily 
 TRP ankyrin channel 1 (TRPA1) is the only known mammalian TRPA channel 
and was first characterized in 2003 as a calcium-permeable, cold-sensing channel (16). 
This subfamily of channels is named “ankyrin” because it has many (~14-17) ankyrin 
repeats in the N-terminal region, depending on the species (16, 17). In humans and 
rodents, TRPA1 expression is documented in a variety of cell and tissue types, including 
the hair cells of the ear, peripheral sensory nerves, and about 20-35% of sensory neurons 
that innervate the respiratory tract (4, 17). In the ear, TRPA1 mechanotransduction 
processes may contribute to auditory signal transduction through tethering of the channel, 
via the ankyrin repeat domain to cytoskeletal components, to generate a “gating spring” 
that promotes channel opening (18). In sensory neurons of the respiratory tract, TRPA1 is 
mainly coexpressed in TRPV1- and tachykinin expressing C-fibers (19).  Rodent TRPA1 
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is strongly activated through covalent modification of residues C415, C422, C622 and 
K208 (20, 21). Many electrophilic and oxidizing chemicals activate TRPA1 to trigger 
cough and abrupt changes in breathing pattern (17). Prototype agonists of TRPA1 include 
sulfur mustards, crotonaldehyde, acrolein, cinnamaldehyde, 4-hydroxynonenal and 4-
oxononenal, isocyanates and isothiocyanates (e.g., allylisothiocyanate), hypochlorous 
acid and hydrogen peroxide, and even cytochrome P450-derived electrophilic metabolites 
of naphthalene (1, 3-5, 17, 19, 21-25). Additional evidence indicates TRPA1 also senses 
cold, and is activated by noxious cold temperatures less than about 19°C.  However, the 
function of TRPA1 in temperature sensation is an area of much debate (4, 26). Finally, it 
should be emphasized that species-specific differences exist in relative potency of these 
agonists, and to date not all of these agents have been shown to activate human TRPA1. 
 
1.1.2 TRPC Subfamily 
 TRPC1 and 3 were the first mammalian homologs of Drosophila trp to be 
identified (1995). This TRP family is called ‘canonical’ (27). TRPC1-7 share >30% 
amino acid homology with each other and also with the Drosophila TRPCs (1). TRPC 
channels form both homo- and heterotetramers (e.g. TRPC1/C4, TRPC4/C5), which has 
considerably complicated deorphanization and characterization of the individual channels 
(9, 28). TRPC channels are primarily activated by calcium store depletion, and in some 
cases, stretch (1, 3, 4). TRPC channels are associated with G-protein coupled receptors 
(G-PCR), such as rhodopsin in Drosophila. Activation of the G-PCR signal transduction 
cascade involves phospholipase-C (PLC), diacylglycerol (DAG) and depletion of calcium 
stores that, through a poorly defined mechanism for these receptors, activates TRPC 
channels (29). In mammals, TRPCs are variably expressed throughout the body.  All 
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human TRPC channel isoforms are expressed in the lung and have a variety of functions 
including mechanosensation, regulation of airway vascular tone, mineral uptake and 
balance, and neuronal growth (1, 3, 4).  TRPC1 and TRPC4 will be discussed at greater 
lengths for their role in maintaining vascular permeability in the lung in section IIIb.  
 
1.1.3 TRPM Subfamily 
 Eight members of the TRPM subfamily have been identified.  TRPM1 was 
initially identified in melanoma cells where expression correlated inversely with the 
metastatic potential, giving rise to the channel’s original name, melastatin (MLSN) (30). 
All genetically related channels were subsequently termed “melastatin” even though their 
functional properties vary widely.  TRPM2 is poorly characterized, but is expressed in 
immune cells and vascular endothelial cells of the lung and is activated by hydrogen 
peroxide and intracellular ADP ribose produced by poly ADP ribose polymerase (PARP) 
during oxidative stress (29). TRPM3 is constitutively active and regulates calcium and 
manganese ion distributions/ion currents across cell membranes, including in vascular 
endothelial cells.  Hypotonic cell swelling can enhance these ion currents (1, 4, 29). 
TRPM4 and TRPM5 are voltage-modulated and can be activated through G-PCRs that 
are coupled to PLC dependent endoplasmic reticulum (ER) calcium release, but are not 
calcium store dependent. (29) TRPM4 and TRPM5 are permeable to monovalent cations, 
but unlike all other TRP channels, are impermeable to calcium ions (4). TRPM5 appears 
to be required for taste because it is present in taste receptor cells, and knockout mice 
(TRPM5-/-) have reduced sweet, bitter and umami responses as measured in vivo by 
gustatory nerve recording, initial lick responses, and two-bottle preference tests (15). 
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TRPM8 is one of only two TRP channels activated by cool temperatures.  TRPM8 
is activated by decreasing temperatures <23 – 28°C and is also activated by “cooling 
agents” such as menthol, icilin, citronellol, and a number of other compounds used in the 
food, cosmetic, and dental industries where “fresh mint” or similar sensations are desired 
(31-33).  TRPM8 is highly expressed in some small diameter unmyelinated sensory 
neurons of the peripheral nervous system and respiratory tract, in certain prostate cancer 
cell lines (e.g., PC-3, but not DU 145), and as a functional N-terminal truncated variant in 
human bronchial epithelial cells, where translation of the protein begins at either M758 or 
M801 (32-36). This variant differs from the full length TRPM8 gene product in its 
sensitivity to prototype agonists that require the high-affinity menthol binding residue 
Y745, or icilin binding sites, located at residues N799, D802, and G805 (34, 37, 38).  The 
variant retains responsiveness to cooling, but is not activated by icilin, and is activated by 
only high concentrations of menthol (34).  TRPM8 likely plays a role in cold 
hypersensitivity, cold allodynia in patients with nerve injuries, and has been proposed to 
possibly play a role in airway hypersensitivity associated with exercising in cold and dry 
air via changes in immunomodulatory cytokine expression and inflammation (34, 39, 40). 
 
1.1.4 TRPML Subfamily 
TRPML1 was identified as a causal mutation for mucolipidosis IV, a severe 
neurodegenerative lysosomal storage disorder (41). TRPML2 and TRPML3 are not yet 
well characterized but are the subject of much research (1, 3, 4). Both TRPML2 and 
TRPML3 have lysosomal targeting signals and reside in the lysosomal membrane (1), but 
TRPML channel expression in the respiratory tract is unknown and will not be discussed 
further in this review.  
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1.1.5 TRPP Subfamily 
TRPP2 is disrupted in some forms of autosomal dominant polycystic disease, 
which lead to the discovery of this channel (29, 42). TRPP channels are expressed in a 
variety of species from worms to mammals, and are thought to be an ancient family of 
channels (1).  TRPP1 and 2 appear to function in ciliary movement while TRPP3 may 
have a role in acid detection and sour taste perception (3). TRPP1 and 2 channels show 
functional importance primarily in the kidney, while TRPP3 has been detected in some 
lung cancers, and TRPP5 is expressed in the testis (4). Very little is known about these 
channels with respect to respiratory physiology or toxicology so they will not be 
discussed further. 
 
1.1.6 TRPV Subfamily 
In 1997, TRPV1 was cloned and identified as the previously elusive target 
receptor for capsaicin, the pungent compound responsible for the sensation of spicy heat 
from chili peppers (43). TRPV1 was called “vanilloid receptor 1” because the prototype 
agonist capsaicin and other natural products that activate this receptor with high 
selectivity contained (or at least mimicked) the vanilloid (4-hydroxy-3-
methoxybenzylamine) pharmacophore (43).  TRPV1 was also identified as a major 
sensor for warm to hot temperatures > 42oC, acidity (pH<6.3), and more recently organic 
acids such as lactate (43-46). Since the discovery of TRPV1, many TRPV1 agonists have 
been reported, ranging from endogenous lipids such as anandamide, leukotriene B4, and 
12(S)-hydroperoxyeicosatetraenoic acid (12(S)-HpETE) to very simple molecules such as 
hydrogen sulfide (H2S) and the cannabinoid !9-tetrahydrocannabinol (47-49). 
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Resiniferatoxin, a compound isolated from Euphorbia Resinifera Berg, is an ultra-potent 
TRPV1 agonist (50).  
Structurally, TRPV1 has the 6 transmembrane domain structure seen in all TRP 
channels.  It is thought that transmembrane domains 3 and 4 form a paddle structure that 
shifts to open and allow for vanilloid binding (51). Jordt et al. described the importance 
of residue Y511 in determining vanilloid sensitivity across species in 2002 (52). Further 
research demonstrated that activation of TRPV1 by capsaicin and other vanilloid agonists 
occurs through specific binding interactions with residues Y511, S512, L547, W549, and 
T550 (51-54). A different site comprised of glutamic acid residues adjacent to the pore-
loop domain is responsible for pH activation and acid potentiation of the channel (44). 
Heat sensitivity (noxious temperatures " 43 °C) is apparently mediated through the C-
terminus of the protein, but the precise residues responsible have not yet been determined 
(55). Although the responses to capsaicin, protons, and heat are integrally related, the 
capsaicin binding site appears to be separate from heat or proton activation domains of 
TRPV1.  
 Many TRPV1 antagonists have been investigated for various applications, 
including therapeutic use for pain treatment. Capsazepine was the first TRPV1 antagonist 
and was designed to be structurally similar to capsaicin (56). Capsazepine has been used 
as a TRPV1 antagonist in many different types of experiments, but its relative lack of 
specificity for TRPV1 has led to many false conclusions regarding TRPV1 activation. 
Another more selective antagonist, 5-iodo-resiniferatoxin, is an iodinated form of 
resiniferatoxin (50, 57). Additional potent and selective TRPV1 antagonists are being 
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developed clinically to alleviate neurogenic pain, although some of them cause 
significant hyperthermia precluding them from clinical use (58-60). 
In addition to TRPV1, other TRPV channels have been discovered based on 
responsiveness to temperature changes and natural products found in spices that 
characteristically induce sensations of temperature change.  TRPV2 activation is highly 
species dependent, and rat TRPV2 is sensitive to noxious heat > 53oC and some 
cannabinoids including !9-tetrahydrocannabinol, cannabinol, and cannabidiol (61-63). 
TRPV3 senses carvacrol (oregano), thymol (thyme), eugenol (clove) and temperatures 
>30oC (64, 65). TRPV4 is a sensor for phorbol esters such as 4#-12,13-didecanoate 
(4#PDD) (rodent only), changes in osmolarity/membrane stretch, and temperatures 
>24oC-34oC (66).  Like TRPV1, these channels are being actively investigated for a 
variety of different functions and therapeutic potential. A role for TRPV4 in lung 
vascular function will be discussed later in this review. TRPV5 and 6 are constitutively 
active, are inhibited by intracellular calcium, and have been implicated in vitamin D-
dependent calcium uptake in the kidney and intestine, respectively (67).  
In the lung, TRPV1-4 are highly expressed in sensory nerves and non-neuronal 
cells including nasal, tracheal, bronchial, and bronchiolar epithelial cells, type 1 and 2 
pneumocytes, resident macrophages, smooth muscle cells, and pulmonary vascular cells 
(4, 14, 68). The specific roles of these channels as sensors of lung toxicants will be 








1.2 TRP Channels as Mediators of Pulmonary Injury 
 
1.2.1  TRPV1, Neurogenic and Non-Neurogenic Inflammation,  
Epithelial Cell Death, and Lung Injury 
In the respiratory tract, TRPV1 is expressed at high levels by unmyelinated C-
fiber neurons, in the somata of sensory ganglia, and in a small population of thin 
myelinated A$-fibers (12, 14, 68).  Neuronal TRPV1 activation results in action 
potentials, which are interpreted as pain and burning sensations.  Additionally, the cough 
reflex is triggered, breathing becomes rapid and shallow, and substance P, calcitonin gene 
related peptide (CGRP), and neurokinin A are released from the nerve termini (12, 17). 
These tachykinins are key mediators of neurogenic inflammation and are involved in 
modulating cell signaling pathways that increase vascular permeability leading to plasma 
extravasation, neutrophil chemotaxis and transmigration into the lung, macrophage 
activation, and pulmonary edema (69-72). 
 TRPV1 is also expressed in a variety of non-neuronal cells of the respiratory tract, 
including tracheal, bronchial and bronchiolar epithelial, alveolar type I and II, airway 
smooth muscle and pulmonary microvascular endothelial cells (73-77).  In cultured 
human lung bronchial epithelial and adenocarcinoma cells, two distinct populations of 
TRPV1 are expressed. Differential activation of each population is also coupled to 
distinct responses (75, 77, 78). Activation of the population of TRPV1 expressed at the 
cell surface promotes cellular calcium entry and is coupled with increases in the 
transcription and ultimate secretion of several key immunomodulatory Th1-type 
cytokines and chemokines including IL-6, IL-8, and TNF# (74, 75, 78). Conversely, 
activation of the main sub-population of TRPV1 that resides on the ER leads to calcium 
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efflux from the ER and calcium accumulation in the cytosol (77). This calcium 
accumulation is coupled with accumulation of unfolded proteins, ER stress and ultimately 
cell death.   
The ER is the major site of protein folding in cells, particularly for secreted and 
membrane embedded proteins. ER stress occurs when there is an accumulation of 
misfolded or partially folded proteins in the ER. ER stress is often initiated when the cell 
undergoes an insult, such as glucose or amino acid deprivation, which decreases protein 
production efficiency. In the case of cell permeable TRPV1 agonists, ER calcium 
depletion leads to ER stress because lower calcium concentrations in the ER destabilize 
partially folded protein intermediates, causing increased sequestration of specific ER 
chaperone proteins (79, 80). Protein folding efficiency in the ER is monitored and, in 
part, regulated by chaperones including calreticulin, calnexin, and heat shock proteins, 
most notably glucose-regulated protein 78kDa (GRP78 a.k.a BiP or HSPA5) (80, 81).  
GRP78 is critical for “sensing” protein processing through binding to regulatory 
domains of three proximal transducers of ER stress: activating transcription factor 6 
(ATF6), inositol requiring enzyme 1 #/% (IRE1#/%), and eukaryotic translation initiation 
factor 2# kinase 3(eIF2#K3 a.k.a PERK). When unfolded proteins accumulate, GRP78 
dissociates from these proximal sensors to initiate the ER stress response, a highly 
orchestrated process intended to restore cellular homeostasis through coordinated up and 
downregulation of specific genes.  The release of GRP78 from ATF6 leads to ATF6 
cleavage and the production of an active transcription factor primarily associated with up-
regulation of membrane synthesis machinery to expand the ER, and induction of 
chaperones to increase the protein folding capacity of the ER.  IRE1#/% activation also 
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acts in this manner via the production of x-box binding protein 1 (XBP-1) transcription 
factor (79, 80, 82, 83). GRP78 dissociation from PERK activates PERK to phosphorylate 
eIF2#, leading to translational attenuation, rapid degradation of select non-essential 
mRNAs (messenger ribonucleic acid), cell cycle arrest due to a loss of cyclin D1 
(CCND1) translation and mRNA degradation, and the induction of genes such as growth 
arrest and DNA damage-inducible protein 153 (GADD153, a.k.a. CHOP and DDIT3) 
that both establish a negative feedback on the ER stress pathways via transcription factor 
activity and promote apoptosis, presumably serving as a protective event to eliminate 
irreparably compromised cells (79, 80, 82-84). 
Various prototypical agonists activate TRPV1 in human lung bronchial epithelial 
cells, leading to ER stress and cell death via activation of the PERK pathway (77). 
GADD153 induction leads to cell cycle arrest at the G1/S transition and the cells 
eventually die (85). Specifically, TRPV1 activation caused ER calcium release, eIF2# 
phosphorylation, GADD153 induction, and cell death. TRPV1-mediated cell death was 
preventable with inhibition of ER calcium release using cell-permeable TRPV1 
antagonists (e.g., LJO-328), prevention of eIF2# dephosphorylation by salubrinal, (86) 
and over-expression dominant negative forms of either eIF2# (eIF2#-S52A) or 
GADD153 (GADD153-L134A/L141A) (77). These studies provided evidence that acute 
epithelial cell damage observed following airway exposure to capsaicin (76) occurs via 
ER stress. Of significance, Endo et al. has shown that GADD153 induction occurs in 
lungs of mice treated with lipopolysaccharides (LPS) following i.p. administration (87). 
Additionally, LPS induced lung injury was attenuated in GADD153-/- mice indicating an 
important role for ER stress in LPS induced lung injury (87, 88). 
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 TRPV1 has also been shown to detect a variety of endogenous compounds 
commonly produced during systemic inflammation. The studies by Endo et al. discussed 
immediately above provide a plausible link between systemic inflammation and lung 
injury involving ER stress (87, 88). However, the role of endogenous TRPV1 agonists as 
intermediate mediators of these outcomes was not explored.  As previously mentioned, 
TRPV1 has many exogenous and endogenous agonists. Endogenous agonists of TRPV1, 
or endovanilloids, play a role in inflammatory responses and are generated at 
concentrations that can activate TRPV1 in local tissue environments after inflammatory 
insults (89).  Endovanilloids include anandamide, n-arachidonyldopamine, H2S, 
leukotriene B4, 12(S)-HpETE, and a variety of other substances typically derived from 
arachidonic acid (47-49). Several studies have also shown LPS treatments in vitro and in 
vivo lead to increases in physiological concentrations of endovanilloids including 
anandamide and H2S (47, 70, 90-97). Another new class of endogenous TRPV1 agonists 
are oxidized linoelic acid metabolites, 9-hydroxyoctadecadienoic (HODE), 13-HODE, 
and 13-oxoHODE, which mediate hyperalgesia, allodynia and contribute to heat 
sensitivity (98, 99).  
Anandamide was first identified as an endogenous cannabinoid receptor agonist, 
and was later shown to act at TRPV1 in addition to cannabinoid receptors 1 and 2 (49, 
100, 101). Anandamide is essentially synthesized ‘on demand’ in the central nervous 
system and at sites of peripheral tissue injury, including the lung, in concentrations 
sufficient to active TRPV1 (68, 102, 103). It is difficult to define the exact physiological 
role of anandamide because it acts differentially through cannabinoid receptors and 
TRPV1 receptors, its concentration is modulated by fatty acid amide hydrolases 1 and 2 
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(FAAH), and some effects may be concentration  and duration of exposure dependent 
(89, 104, 105). In guinea pigs, TRPV1 activation by aerosolized anandamide induces 
cough, and in isolated guinea pig bronchi, anandamide treatment causes 
bronchoconstriction (105, 106). Additional studies indicate that intraluminal 
administration of Clostridium difficile toxin A stimulates the production of anandamide, 
which then acts through TRPV1 to cause significant ileal inflammation (107). The 
hypothesis that TRPV1 activation by endovanilloids during inflammation exacerbates 
injury is supported by evidence that anandamide is upregulated during endotoxemic 
events, and inflammatory mediators potentiate anandamide effects at TRPV1 (89, 94, 95, 
108, 109). Systemic inflammation and infection often lead to cardiovascular collapse, and 
anandamide has been proposed as a mediator of endotoxin induced hypotension because 
it potentiates vasodilation in LPS treated animals and is measurable in septic conditions 
(94, 108, 109).  
In animal models, LPS treatment causes marked, and often unbalanced, systemic 
inflammation via the activation of Toll-like receptor 4 on macrophages (110-116). LPS 
induced inflammation is characterized by hyperthermia (calor), vascular leakage, 
hypotension, erythema/reddening of the site (rubor), and hyperalgesia (dolor), 
progressive loss of organ functions, and lung injury generally characterized by 
neutrophilia and pulmonary edema.   
LPS treatment, as well as other models of severe infection and lung injury, 
including cecal ligation and puncture, also cause increases in the production of, and 
systemic/circulating concentrations of, H2S (48, 90, 91, 117-121). H2S is a purported 
TRPV1 agonist, and was also shown to activate TRPA1 in rat bladder and mouse and 
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human TRPA1 expressed in CHO cells (48, 122).  TRPV1 antagonist cotreatment, or 
capsaicin sensitive efferent neuron depletion via long term, high dose capsaicin (sub-
cutaneous) pretreatment, have been shown to attenuate lung injury after treatment with 
H2S donors, LPS treatment, and cecal ligation and puncture (70, 90, 118). These 
beneficial effects were attributed to decreased release of substance P, CGRP, and 
neurokinins by TRPV1 expressing sensory neurons.  Accordingly, protective effects were 
observed in capsazepine and n-propargylglycine (an inhibitor of H2S synthesis) cotreated 
animals and preprotachykinin A (PPTA-/-) deficient mice (91, 96, 97, 118, 123, 124). 
Preprotachykinin A codes for substance P and neurokinin A, which are both expressed by 
capsaicin sensitive neurons in the lung and are potent mediators of neurogenic 
inflammation (125).  These experiments illustrated that H2S and TRPV1 contribute to 
lung injury via TRPV1, and possibly TRPA1, activation and indicate a broader role for 
TRPV1 and endovanilloids as a mediators of both inflammation and lung injury due to 
systemic inflammation, such as sepsis.   
To date, studies of additional endovanilloids that may contribute to lung injury as 
a result of systemic inflammation, independent of infection/simulated infection, including 
burn injury or severe trauma have not been performed. However, literature does indicate 
that some endovanilloids are produced under these conditions and that lung injury is due 
to substance P production (126-128).  
 The role of TRPV1 in airway inflammation and lung injury is not simply 
mediated through neurogenic inflammation. Inflammatory mediators and changes in 
cellular microenvironment both in the lung and at other sites of injury can activate 
TRPV1. Stimulation of TRPV1 in non-neuronal cells causes rapid increases in key 
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immunomodulatory cytokines that regulate innate immune responses, including the 
release of IL-8 to promote neutrophil chemotaxis and TNF# and IL-6 to activate 
macrophages and to stimulate downstream events required to balance the immune 
response.  Of significance, TRPV1 activation in the lung is not an all-or-none event 
leading to neurogenic inflammation and injury.  It has been shown that activation of 
TRPV1 also promotes the release of somatostatin from sensory neurons, which acts to 
mitigate the severity of inflammation and lung injury (129, 130). 
 Overall, the role of TRPV1 and other TRP channels, including TRPA1 and 
TRPV4, in lung injury is slowly becoming clearer. TRPV1 is a promising therapeutic 
target for treatment and prevention of inflammatory lung injury.  
 
1.2.2  TRP Channels in Lung Vasculature: Key Players  
in Endothelial Barrier Function, Mechanotransduction,  
and Lung Injury 
 TRP channels are also rapidly emerging as principle regulators of lung vascular 
endothelial cell function, specifically in the areas of inflammation, mechanotransduction, 
and inflammatory and hypertensive lung injury.  Select TRP channels perform important 
roles in modulating lung vascular barrier function in a segment specific manner. It is 
quickly becoming apparent that coordinated calcium fluxes, second messengers, and 
other unidentified signals coalesce to produce an integrated lung endothelial barrier 
response to locally produced (i.e. in the lung) and systemically circulating cytokines, 
neurally generated signals, and changes in pulmonary vascular pressure and airway 
distension.  The pivotal roles of select TRP channels in regulating vascular permeability 
and the importance of this event in lung injury proposes a role for certain TRP channels 
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as mediators of lung injury resulting from pathological conditions including 
hypertension, sepsis, and ventilator induced lung injury (VILI).   
 It has been appreciated for almost two decades that changes in intracellular 
calcium are a primary event leading to altered vascular endothelial barrier function (131). 
Calcium-induced changes in junctional patency occur through processes that are linked to 
the endothelial cell contractile apparatus (132, 133) and the production of other 
intracellular mediators such as nitric oxide and reactive oxygen species which both have 
known effects on TRP channels including TRPV1, TRPV4, TRPA1, and possibly 
TRPM2 (17, 19, 134-137).  The role of ER calcium release versus calcium influx from 
extracellular sources in endothelial activation and changes in barrier function was 
debated for many years, but it is now clear that these two calcium fluxes are linked and 
represent a coordinated response that is TRP channel mediated and directly linked to 
changes in barrier function under a diverse range of pathological conditions (138). 
 A sentinel observation on the role of endothelial calcium perturbations on barrier 
regulation was that calcium influx from external sources, and not ER release, was the 
signal for alterations in permeability (139). Thus arose the concept that ER calcium 
depletion was the trigger for calcium influx, leading to the term store operated calcium 
(SOC) entry. This concept ultimately defined the general mechanism(s) that linked 
calcium fluxes with barrier dysfunction (140).  
The TRP family of cation conducting channels has become the central focus of 
SOC entry and calcium mediated barrier dysfunction.  TRPC1 and TRPC4 appear to be 
the major participants in lung endothelial calcium fluxes that are germane to permeability 
regulation based on the following observations.  The use of antisense RNA to reduce 
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TRPC1 expression in cultured pulmonary artery endothelial cells (141) effectively 
reduced SOC currents (ISOC), and endothelial cells derived from TRPC4 knockout 
animals showed no evidence of an inducible ISOC.  There is also substantial evidence to 
suggest TRPC1 and TRPC4 interact, perhaps by heteromultimerization or via co-
localization (138) to coordinate calcium flux in response to challenges.   
Studies comparing the relationship between calcium responses and barrier 
function in macrovascular (rat pulmonary artery endothelial cells, RPAEC) versus rat 
lung microvascular endothelial cells (RLMVEC) have also been key in elucidating the 
roles of TRPC channels in permeability regulation. Marked differences were observed 
between these two cell types. RLMVEC formed tighter, more restrictive, junctions to 
macromolecules and did not demonstrate increased permeability in response to increases 
in intracellular calcium (142). However, RLMVEC exhibited lower thapsigargin induced 
flux (i.e., lower intracellular calcium store content) compared to RPAEC, higher SOC 
entry in response to stimuli, and a reduced permeability response to increased [Ca++]i.  
Collectively, these observations suggested an uncoupling of calcium from permeability in 
RLMVEC. RLMVEC cells exhibit lower TRPC1 and TRPC4 expression, further 
indicating a role of these TRPs in control of vascular integrity and fluid flux across this 
barrier.  Down regulation of TRPC1 and TRPC4 has recently been reported in a rat model 
of heart failure and was associated with reduced thapsigargin induced permeability, 
suggesting a clinically relevant direct correlation of TRPC channel expression during a 
pathological process that usually results in pulmonary edema (143). 
 The functional differences in macrovascular versus microvascular endothelial cell 
properties have subsequently been extended to in vivo studies, where the anatomical 
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correlates, extra-alveolar vs. alveolar vessel permeability, was examined as a function of 
site specific stimulation with either thapsigargin or 4#PDD.  Thapsigargin is known to 
increase permeability of extra-alveolar vessels through depletion of ER calcium stores via 
sarco/endoplasmic reticulum Ca2+ATPase (SERCA) inhibition, while 4#PDD appears to 
preferentially activate TRPC4 (144) and increases alveolar capillary permeability.  This 
differential activation of TRPC channels in different vascular segments produced 
distinctly different patterns of fluid accumulation; thapsigargin caused fluid cuffing 
around large vessels while 4#PDD increased alveolar flooding (145) suggesting regional 
differences in TRPC channel expression, as indicated by previous in vitro studies.  The 
mechanical properties of the lung were also differentially altered by the site-specific 
leakage induced by thapsigargin and 4#PDD; dynamic compliance was reduced by the 
presence of extra-alveolar cuffing, but not by alveolar flooding.  Thus, vascular specific 
TRP channel expression in the lung and the cellular response to calcium via TRP 
channels influences the permeability response to injury, and the subsequent mechanical 
sequela that may be involved in lung injury and/or lung diseases.   
 Rodent TRPV4 is also activated by 4#PDD in vascular cells. Recent studies have 
shown that TRPV4 activation also causes alveolar-specific injury and contributes to 
alveolar flooding as previously suggested for TRPC4 (144, 145). In fact, TRPV4 may be 
the primary mediator of alveolar flooding caused by 4#PDD, based on studies using more 
selective agonists and inhibitors of cytochrome 450 enzymes that attenuate the formation 
of the endogenous TRPV4 agonists 5,6-epoxyeicosatrienoic acid (EET), 8,9-EET and 
14,15-EET (146, 147). Vriens et al. showed that sulfaphenozale inhibition of cytochrome 
P450 2C enzymes lessened arachidonic acid stimulated TRPV4 currents by inhibiting 
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EET formation (147). Consider also the effects of GSK1016790A, a potent TRPV4 
agonist that upon administration causes immediate loss of vascular integrity and massive 
pulmonary edema characterized by alveolar flooding (148).  Similarly, activation of 
TRPV4 with 5,6- or 14,15-EET increased the whole lung filtration coefficient (Kfc) in a 
dose and calcium dependent manner.  The increases in Kfc were blocked by the cell 
surface (impermeable) calcium channel blocker ruthenium red, but not by thapsigargin 
induced ER calcium depletion (146). When 4#PDD was tested in TRPV4 knockout mice, 
there was no change in Kfc but electron microscopy confirmed cellular pathology and 
demonstrated widened intercellular gaps that were confined to the alveolar capillaries. 
This supports the notion that the lung vascular barrier is regulated by distinct expression 
patterns of TRP channels, namely TRPC1, TRPC4 and TRPV4, and associated site 
specific influences on calcium permeability (146).   
 TRPV4 has also been shown to participate in VILI.  Mice ventilated with high 
peak inspiratory pressure (PIP, 35 cm H2O) demonstrated a 2.2-fold increase in Kfc that 
could be blocked by ruthenium red, methanandamide (a cannabinoid receptor antagonist; 
mainly blocks CB1) and miconazole (a cytochrome P450 epoxygenase inhibitor).  When 
TRPV4 knockout mice were ventilated with identical high PIP there was no measurable 
increase in Kfc.  In parallel experiments, PIP induced calcium entry into endothelial cells 
was measured using Fura-2.  High PIP induced calcium was absent in TRPV4 deficient 
mice and in wild type mice, but only when cotreated with ruthenium red (149).  
Collectively, these results suggest a role for TRPV4 in acute lung injury and VILI.  These 
results also suggest that endogenous TRPV4 agonists, which may be produced during 
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sepsis and other inflammatory conditions, promote lung injury.  To date, however, this 
paradigm has not been investigated.  
 The topic of lung vascular mechanotransduction also has become an important 
mechanism for the development of pulmonary edema, particularly during states such as 
congestive heart failure and VILI when pulmonary capillary pressure is increased.  
Bhattacharya and colleagues demonstrated that elevated pulmonary capillary pressure 
increased endothelial cell calcium content (150), mitochondrial reactive oxygen species 
production, P-selectin expression (151) and leukocyte margination (152); events that link 
mechanotransduction with inflammatory responses that contribute to lung injury.  
Kuebler et al. (153) reported that pressure induced increases in cellular calcium activated 
endothelial nitric oxide synthase (eNOS) leading to an increase in nitric oxide, a known 
mediator of endothelial permeability responses and recently identified modulator of select 
TRP channels (137).  High airway pressures could induce similar changes in lung 
capillary endothelial nitric oxide, suggesting that alveolar signals may cause alterations in 
the vascular barrier in response to airway forces. This process is potentially mediated via 
activation of TRP channels on epithelial cells and sensory nerves, which subsequently 
release factors that affect endothelial cells (e.g., tachykinins, cytokines, or arachidonic 
acid metabolites).  Jian et al. (154) showed that the lung capillary response to high 
vascular pressure involved cytochrome P450 epoxygenase dependent activation of 
TRPV4, presumably involving 5,6- or 14,15-EET, leading to increased Kfc and vascular 
leakage.  Increases in lung capillary pressure to 30 cm H2O resulted in a significant 
increase in Kfc, which was significantly reduced in TRPV4 knockout mice.  Using lower 
capillary pressures (15 cm H2O) Yin et al. (155) suggested that high vascular pressure 
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activated a negative feedback loop involving nitric oxide cyclic guanosine 
monophosphate (NO-cGMP) that inhibited TRPV4 and attenuated further increases in 
endothelial permeability.  The lower vascular pressures (15 cm H2O) and the use of 
statically inflated lungs by Yin et al., as opposed to cyclically ventilated lungs, may 
contribute to the different responses highlighting the summation of airway and vascular 
forces into an integrated response controlled to a significant degree by TRP channel 
function. 
 How mechanosensitive ion channels like TRPC1, TRPC4 and TRPV4 are 
activated by physical forces remains largely unknown.  Direct interaction of stretch 
activated channels with elements of the cytoskeleton, akin to the hypotheses for TRPA1 
in auditory function, has received the most attention (156). Several excellent reviews on 
TRP channels and mechanotransduction are available (157, 158) that discuss the TRP 
family structure function relationship.  In endothelial cells, the ER is in close apposition 
to the plasma membrane (159, 160) and, therefore, likely to be in close proximity to sub-
membranous cytoskeleton elements including spectrin, protein 4.1 and actin.  Antibodies 
directed against the spectrin-4.1 protein complex abolished thapsigargin activated ISOC, 
suggesting a role for structural proteins in regulating channel function (140). TRPC, 
TRPA, TRPV and TRPN channels all possess multiple conserved ankyrin binding 
domains that may link the channel with other structural proteins including actin.  There is 
a paucity of information, however, to conclude that channel cytoskeletal interaction 
accounts solely for channel regulation. Other factors such as modification of TRP 
channels by nitrosylation (e.g., TRPV1), other forms of post-translational modification, 
or the synthesis of endogenous TRP channel agonists may also regulate TRP channel 
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function and responses to mechanical stimuli.  Accordingly, the combined actions of 
mechanical stress and secondary biochemical activation may better model the time-
dependency and pharmacological inhibition of TRP-mediated responses. 
 
 
1.3  Air Pollution, Particulate Pollutants, TRP Channels,  
and Lung Injury 
 Respiratory irritants and toxicants including industrial chemicals, geological 
dusts, combustion-derived particulates, smoke components, and other respirable 
substances pose a severe threat to human health (161-172).  Epidemiological studies have 
associated air pollution with adverse health effects ranging from school absences to 
increased rates of cardiovascular- and cardiopulmonary-related hospitalizations and 
deaths, motivating scientists to elucidate how pollution components cause deleterious 
effects on multiple levels.   
Inhalation exposure to environmental pollutants is associated with pulmonary 
inflammation, airway epithelial and respiratory cell damage, respiratory dysfunction, 
increased susceptibility to infection, and the exacerbation of chronic respiratory diseases 
including asthma and COPD.  In the National Mortality and Morbidity Air Pollution 
Study (NMMAPS) of the 90 largest U.S. cities, a 0.21% ± 0.06 and 0.31% ± 0.09 
increase in daily total and cardiopulmonary mortality was observed for each 10 µg/m3 
increase in particulate matter (PM) &10 mm median-mass aerodynamic diameter (PM10) 
measured over a 24-hour period (173).  In asthmatic children, PM10 exposure is 
associated with a lower forced vital capacity (FVC), forced expiratory volume (FEV1), 
and maximal midexpiratory flow (174).  Fetal growth and development are impaired by 
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maternal exposure to PM (175), and increased infant mortality due to respiratory illness is 
also associated with PM exposure (176). Infants, children, and the elderly are more 
sensitive to PM-induced respiratory complications, although mechanisms for these 
differences in sensitivity remain undefined.   
 Consequences of human exposure to PM (including homogenous particle 
preparations made for medical or industrial purposes) depend upon the source of PM, 
specific chemical and physical properties, and dose, including the route of exposure. 
Arguably, the most critical route of human exposure to environmental PM and pollutant 
gases is inhalation since the respiratory tract is sensitive to injury, is a direct route to 
deliver agents to systemic circulation, and is a vital organ.  Suspended environmental 
particles are generally separated by size ('m) into coarse (PM10-2.5), fine (PM2.5) and 
ultrafine (PM0.1) fractions (177).  All fractions of PM are capable of entering the 
respiratory tract, but the deposition of inhaled PM in the respiratory tract is size-
dependent.  Larger particles and aggregated submicron particles primarily deposit in the 
nose and upper respiratory tract, mainly the tracheobronchial region, while small particles 
(~PM2.5) show greater deposition in middle and lower airways.  Ultrafine or nanosized 
particles (PM0.1) are short lived because of a tendency to coalesce, but due to deposition 
in alveolar regions and a unique ability to enter the general circulation, PM0.1 are 
potentially more toxic to distant organs, again depending upon their composition and 
associated chemical and physical properties.  In other words, the size, shape, and 
deposition properties of inhaled PM are key, but are not the only factors that determine 
their disposition in the lung. 
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 Inflammation, lung cell damage, and respiratory distress often occur in animals 
and humans exposed to high concentrations of PM.  Although different particles exhibit 
different potencies, respiratory tract responses to PM are strikingly uniform from particle 
to particle, despite the immense heterogeneity in PM composition and inherent 
differences in cells that are exposed to different components or forms of PM.  For a 
single lung cell type, many of the same signaling cascades are activated (e.g., mitogen 
activated and extracellular regulated kinases, NF-(B and antioxidant responses) and 
similar changes in gene expression profiles (e.g., IL-6, IL-8, TNF# and others) are 
observed even when vastly different PM types are used.  The converse is also often true 
for a single PM sample applied to different cell types.  However, exceptions exist, and it 
is generally accepted that differences in the expression of yet undefined cellular 
determinants are the basis of differential reactivity to PM.   
 Accumulating evidence indicates that a limited subset of gene products may 
ultimately determine how the lung responds to PM. Responses of different cells to 
different forms of PM are likely the result of which gene products are expressed, in what 
cellular location they are expressed, and to which pathways they are coupled.  However, 
the precise gene products that detect PM and ultimately initiate responses have not been 
fully established making it difficult to formulate comprehensive models of toxicity. Early 
evidence that lung cell responses to PM may be mediated by specific gene products of the 
TRP family emanate from studies showing that many cellular responses to PM can be 
mimicked by treating cells or animals with synthetic homogenous PM (178-181), pure 
chemical agents such as the TRPV1 agonist capsaicin (73, 76, 181-183), and the TRPA1 
agonists acrolein and crotonaldehyde (184-187). These TRPA1 agonists can be found in 
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certain forms of PM, oxidants (22, 188, 189), and acid aerosols (22) that elicit responses 
similar to PM. Additionally, studies showing that pretreatment of animals with capsaicin 
to delete pulmonary sensory nerves that express TRPV1 and that the TRPV1 antagonist 
capsazepine attenuates responses to PM suggests that these TRP channels may be 
important mediators of PM toxicity.  
 Currently, only a few examples exist where a specific receptor or “PM sensor” is 
responsible for the majority of the cellular responses to certain forms of PM or select 
components of PM.  First is the toll-like receptor 4 for LPS, a common, but not 
ubiquitous component of environmental dusts.  The lipid A moiety of LPS binds to CD14 
and toll-like receptor 4 on pulmonary macrophages (190, 191) resulting in the activation 
of mitogen activated kinases (MAPK), which promotes NF-kB dependent transcription of 
a variety of proinflammatory genes. Additional examples include the epidermal growth 
factor receptor (EGFR, ErbB1) and the macrophage scavenger receptor MARCO (192-
197) for silica.  However, while these three receptors appear to be important determinants 
of responses to select forms of PM in the lung, they do not represent a unifying 
mechanism explaining the effects of different PM and antagonists on different lung cell 
types, or even composite responses of the intact lung. Additional gene products must also 
have the capacity to differentially detect select forms of PM and initiate responses that 
contribute to the overall effects in the lung.   
 There are several hypotheses explaining how PM toxicity is manifested in the 
lung.  Studies have correlated cellular responses with PM size, shape, redox active 
transition metal (Cu+/2+ and Fe2+/3+) content and leachability, and even the presence or 
absence of adsorbed, but often unidentified organics.  However, these correlations have 
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been disproven in large studies of PM and different cell types suggesting that they are 
specific for a limited set of PM and cell types. 
 An evolving hypothesis focuses on TRPV1.  In several studies, TRPV1 was found 
to be a key molecular determinant and mediator of the inflammatory and cytotoxic effects 
of PM (179, 181-183, 198-200). Epithelial cells lining the nasal passages and major 
airways are arguably the first cells to encounter inhaled PM due to both their location and 
abundance.  Thus, these cells are likely early responders to irritating airborne stimuli, 
such as PM (74).  Additionally, sensory neurons that terminate immediately below the 
epithelial cell layers of the respiratory tract are critical mediators of behavioral, reflex and 
molecular responses to many toxicants adsorbed to PM and also likely initially respond to 
PM or its components.   
As discussed previously, neurogenic inflammation involves the activation of 
various sensory receptors including TRPV1 and TRPA1.  Evidence linking sensory 
nerves and TRPV1 to PM responses includes the following:  TRPV1 postive C-fiber 
depletion in animals by capsaicin pretreatment reduces plasma extravasation evoked by 
pollutants in airways (200) and attenuates many neuronally mediated responses (e.g., 
cough, apnea, cardiac arrhythmia and oxidative stress, and inflammation) elicited by PM 
(201, 202) and other components of air pollution (96, 125, 203). Accordingly, 
capsazepine, a moderately selective TRPV1 antagonist, has also been shown to prevent 
several responses to PM and other known components of air pollution (201).  However, 
capsaicin pretreatment can also exacerbate lung injury after exposure to some PM, 
including diesel exhaust PM (DEP) suggesting TRPV1 positive sensory nerves may also 
fetter the immune response, potentially via somatostatin as shown for LPS. Alternate 
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pathways must also contribute to PM-induced lung injury, including the activation of 
additional receptors, TRPV1 deficient sensory nerves, and other cell types.   
 The ability of nonneuronal lung cells to initiate proinflammatory responses to PM 
has been known for some time, but the involvement of a specific “PM sensor” was first 
shown in seminal studies by Agopyan et al. (73, 178, 179) and Veronesi et al. (181-183, 
198) TRPV1 and acid sensing (ASIC) ion channels expressed by immortalized (BEAS-
2B) and primary (NHBE and SAEC) airway epithelial cells were activated by PM that 
carried a net-negative surface charge (i.e., a negative zeta potential) and activation was 
coupled with elicited cytokine/chemokine (i.e., IL-6, IL-8, and TNF#) production and 
apoptosis (73, 178, 181-183, 198).  Furthermore, TRPV1 activation was enhanced by 
sensory neuropeptides (i.e., CGRP and substance P), suggesting that complementary 
interactions between sensory neurons and epithelial cells occur in the intact lung.  These 
results were significant for several reasons:  they identified specific gene products that 
detect PM, established plausible mechanisms of action at the molecular level, and 
demonstrated that lung epithelial cells also contribute to the deleterious effects of PM in 
the intact lung since the expression of TRPV1 in lung epithelial cells is not eliminated by 
capsaicin pretreatment.  As such, the ability of TRPV1 to be activated by PM in airway 
epithelial cells is likely a contributory factor to composite responses to PM. 
 To date, the activation of other TRP channels by particulate pollutants has not 
been evaluated. Correlations between biological activity of particulate materials, 
inhibition by antioxidants, transition metal content, oxidant potential, organic carbon 
content, acidity, and their ability to produce lipid aldehydes strongly suggest that TRPA1 
may be an additional mediator of particulate pollutant toxicities in the lung.  
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Interestingly, multiple components of ambient particulate materials (e.g., acrolein and 
crotonaldehyde) are potent agonists of TRPA1 (19, 22, 187, 204, 205), and not TRPV1, 
suggesting that the origin and composition of ambient particles will impact the ability of 
TRPV1 and/or TRPA1 to ultimately sense PM and initiate deleterious processes such as 
neurogenic or epithelial cell-derived inflammation and damage.   
 Understanding the pathways by which PM elicits adverse effects in the lung is 
complicated by the heterogeneous composition of pollutants as well as the diverse 
responses observed after exposure.  However, by identifying target receptors for different 
PM or components of PM, such as TRPV1, TLR-4, etc, the construction of a more 
defined mechanism associating PM and adverse health effects will be feasible.  Thus, 




 TRP channels are central to respiratory physiology: as pulmonary sensors of 
potentially deleterious stimuli; as regulators of reflex responses such as cough, changes in 
breathing pattern; as initiators of innate immune responses; and for maintenance of 
vascular barrier function. TRP channels are now recognized as critical for the 
maintenance of normal pulmonary physiology and as key mediators of pulmonary injury 
elicited by both endogenous and exogenous stimuli.  The TRP channel field is exciting 
and rapidly advancing, and will continue to enhance our understanding of sensory 
physiology, and the mechanisms through which these channels regulate normal and 
abnormal respiratory conditions.  TRPV1 antagonists will continue to be developed for 
pain treatment and it is likely that the availability of such probes will continue to advance 
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the field of TRP channels in respiratory physiology.  Additional research is expected to 
elucidate how endovanilloids, TRPV1, and other endogenous agents and TRP channels 
contribute to lung injury during systemic inflammation and through direct channel 
activation by agonists. Understanding of TRP channels in respiratory disease may lead to 
novel treatment modalities for complicated and often lethal disease states such as acute 
respiratory distress syndrome (ARDS), asthma, COPD, or chronic lung disease associated 
with mechanical ventilation.  Finally, identification of select TRP channels as sensors for 
respiratory irritants and air pollutants such as PM will help establish more precise 
cause/effect relationships for environmental lung diseases, improving our ability to link 
the morbidity and mortality associated with high pollution events with distinct cellular 
responses and susceptibility factors.    
 Additional chapters in this dissertation will focus on the pharmacology and 
physiology of TRPV1 in the lung epithelium. Research showing how TRPV1 induces ER 
stress and lung cell death will be presented in Chapter 2. Chapter 3 will discuss the 
structure activity relationship between capsaicinoid analogues and TRPV1, highlighting 
structural features of capsaicin and nonivamide that are essential for TRPV1 activity. 
Chapter 4 will examine TRPV1 as a mediator of lung injury in mice after LPS treatment, 
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ABSTRACT
Transient receptor potential vanilloid 1 (TRPV1) is a calcium-
selective ion channel expressed in human lung cells. We show
that activation of the intracellular subpopulation of TRPV1
causes endoplasmic reticulum (ER) stress and cell death in
human bronchial epithelial and alveolar cells. TRPV1 agonist
(nonivamide) treatment caused calcium release from the ER
and altered the transcription of growth arrest- and DNA dam-
age-inducible transcript 3 (GADD153), GADD45, GRP78/BiP,
ATF3, CCND1, and CCNG2) in a manner comparable with
prototypical ER stress-inducing agents. The TRPV1 antagonist
N- (4-tert-butylbenzyl)-N -(1-[3-fluoro-4-(methylsulfonylamino)-
phenyl]ethyl)thiourea (LJO-328) inhibited mRNA responses and
cytotoxicity. EGTA and ruthenium red inhibited cell surface
TRPV1 activity, but they did not prevent ER stress gene re-
sponses or cytotoxicity. Cytotoxicity paralleled eukaryotic
translation initiation factor 2, subunit 1 (EIF2) phosphorylation
and the induction of GADD153 mRNA and protein. Transient
overexpression of GADD153 caused cell death independent of
agonist treatment, and cells selected for stable overexpression
of a GADD153 dominant-negative mutant exhibited reduced
sensitivity. Salubrinal, an inhibitor of ER stress-induced cyto-
toxicity via the EIF2K3/EIF2 pathway, or stable overexpres-
sion of the EIF2-S52A dominant-negative mutant also inhib-
ited cell death. Treatment of the TRPV1-null human embryonic
kidney 293 cell line with TRPV1 agonists did not initiate ER
stress responses. Likewise, n-benzylnonanamide, an inactive
analog of nonivamide, failed to cause ER calcium release, an
increase in GADD153 expression, and cytotoxicity. We con-
clude that activation of ER-bound TRPV1 and stimulation of
GADD153 expression via the EIF2K3/EIF2 pathway repre-
sents a common mechanism for cytotoxicity by cell-permeable
TRPV1 agonists. These findings are significant within the con-
text of lung inflammatory diseases where elevated concentra-
tions of endogenous TRPV1 agonists are probably produced in
sufficient quantities to cause TRPV1 activation and lung cell
death.
Lung cell damage causes acute respiratory distress and
contributes to the pathogenesis of chronic lung diseases
(Knight and Holgate, 2003). Evidence suggests that the tran-
sient receptor potential vanilloid type-1 receptor (TRPV1,
capsaicin receptor, VR1; Hs. 268606) may be a mediator of
lung pathologies caused by xenobiotic toxicants and endoge-
nous agonists as well as a therapeutic target for treating
and/or preventing lung disorders (Jia et al., 2005; Szallasi et
al., 2006).
TRPV1 is widely expressed in the respiratory tract, includ-
ing nasal mucosal cells (Seki et al., 2006), C-fiber neurons
and airway smooth muscle cells (Mitchell et al., 2005; Wa-
tanabe et al., 2005), and alveolar and bronchial epithelial
cells (Veronesi et al., 1999; Reilly et al., 2003; Agopyan et al.,
2004). TRPV1 is selectively activated by capsaicin, the pri-
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mary pain-producing chemical in hot peppers, and a variety
of exogenous and endogenous respiratory toxicants, includ-
ing anandamide (Van Der Stelt and Di Marzo, 2004), prod-
ucts of arachidonic acid metabolism by lipoxygenases
(Hwang et al., 2000), H2S (Trevisani et al., 2005), ethanol
(Trevisani et al., 2004), acids (Tominaga et al., 1998; Ric-
ciardolo et al., 2004), and particulate pollutants (Veronesi et
al., 1999; Agopyan et al., 2004). Capsaicin and other TRPV1
agonists are routinely used to study the TRPV1 pharmacol-
ogy and have proven instrumental in defining the physiolog-
ical roles of TRPV1 in the lung and other organs. Here, we
use capsaicin to elucidate toxicological phenomena associ-
ated with TRPV1 activation in lung cells.
Capsaicin is used clinically to induce cough (Morice et al.,
2001) and to treat rhinitis (van Rijswijk and Gerth van Wijk,
2006). However, numerous case reports have described ad-
verse respiratory effects and death in humans following ex-
posures to concentrated capsaicinoid aerosols (Heck, 1995;
Steffee et al., 1995; Billmire et al., 1996). In animal models,
high doses of capsaicin cause acute respiratory and cardio-
vascular failure, independently of the route of administration
(Glinsukon et al., 1980). Inhalation of capsaicinoids by rats
causes lung inflammation and widespread damage to tra-
cheal, bronchial, and alveolar cells (Reilly et al., 2003). In
vitro studies with human bronchial epithelial cells have dem-
onstrated two principal outcomes associated with TRPV1
activation: proinflammatory cytokine (interleukin-6 and in-
terleukin-8) production and oncotic cell death (Reilly et al.,
2003, 2005). Cytokine synthesis and cell death were inhibited
by TRPV1 antagonists that prevented calcium release from
the endoplasmic reticulum (ER) and included LJO-328,
SC0030, and 5-iodo-RTX. Conversely, inhibition of the cell
surface population of TRPV1 using EGTA, ruthenium red,
and calcium-free media only prevented cytokine responses.
In mammalian cells, depletion of ER calcium initiates a
homeostatic stress response program termed ER stress. ER
stress is generally initiated by a reduction in protein process-
ing efficiency in the ER, and its roles in human diseases and
xenobiotic toxicities have been reviewed (Cribb et al., 2005;
Schroder and Kaufman, 2005; Zhang and Kaufman, 2006).
ER stress is predominantly regulated by three sensors: acti-
vating transcription factor 6 (ATF6; Hs. 492740), eukaryotic
initiation factor 2 kinase-3 (EIF2K3 or PERK; Hs.
591589), and ER to nucleus signaling 1 and 2 (a.k.a. IRE1
and ; Hs. 133982 and Hs. 592041) (Schroder and Kaufman,
2005). Activation of one or more of these proximal sensors is
dependent upon the type of cellular stress. For example, the
prototypical ER stress-inducing agent thapsigargin preferen-
tially activates the “translational branch” involving
EIF2K3. Activated EIF2K3 catalyzes the phosphorylation
of cytosolic EIF2 (Hs. 151777) (Lu et al., 2004; Boyce et al.,
2005). Heterodimerization of EIF2-P with EIF2 promotes
ATF4 translation (Hs. 496487) and inhibits the translation of
“nonessential” genes (Wek et al., 2006). ATF4 translocates to
the nucleus where it modulates the expression of a subset of
stress-response genes that include ATF3, GADD153,
CCND1, and BiP/GRP78 (see Table 1 for UniGene identifi-
cations numbers). Phosphorylation of EIF2 is considered
protective (Lu et al., 2004; Boyce et al., 2005), but increased
expression of GADD153, as a consequence of EIF2 phos-
phorylation, causes cell cycle arrest at G1/S and cell death
(Oyadomari and Mori, 2004).
In this study, we tested the hypothesis that activation of
the intracellular ER subpopulation of TRPV1 by prototypical
and endogenous TRPV1 agonists would disrupt ER calcium
homeostasis and activate EIF2K3-dependent ER stress re-
sponses to cause cytotoxicity. The data obtained from this
work imply that a common mechanism of cytotoxicity exists
for cell-permeable TRPV1 agonists and that conditions that
promote TRPV1 activation in vivo (e.g., inflammation, inha-
lation of polluted air) may promote lung pathologies through
TRPV1- and EIF2K3-dependent procytotoxic ER stress
pathways.
Materials and Methods
Chemicals. Structures of the TRPV1 agonists and antagonists
used in this study are shown in Fig. 1. Nonivamide (n-vanillyl-
nonanamide), sulfinpyrazone, dithiothreitol (DTT), H2O2, ruthenium
red, EGTA, benzylamine-HCl, and nonanoyl chloride were pur-
chased from Sigma-Aldrich (St. Louis, MO). LJO-328 was generously
provided by Dr. Jeewoo Lee (Seoul National University, Seoul, Ko-
rea). Thapsigargin and 5-iodo-resiniferatoxin were purchased from
Axxora Life Sciences, Inc. (San Diego, CA). Salubrinal (EIF2-inhib-
itor) was purchased from Calbiochem (San Diego, CA). PCR primers
were purchased from Integrated DNA Technologies (Coralville, IA).
n-Benzylnonanamide was synthesized by reacting benzylamine-HCl
and nonanoyl chloride in 0.1 M NaOH and collecting the precipitate.
Product structure was verified by liquid chromatography-tandem
mass spectrometry (m/z 248) and 1H and 13C NMR. Purity was
estimated to be 98% by high-performance liquid chromatogra-
TABLE 1
Primer sequences used for RT-PCR analysis of selected ER stress-responsive genes
Gene Name, UniGene ID PCR Product Size(Nucleotides) Primer Sequence
GADD153, Hs. 505777 395 () 5-GACCTGCAAGAGGTCCTGTC-3
() 5-TCGCCTCTACTTCCCTGGTC-3
GADD45, Hs. 80409 258 () 5-TCTCGGCTGGAGAGCAGAAG-3
() 5-CGCGCAGGATGTTGATGTCG-3
BiP/GRP78, Hs. 605502 296 () 5-CGTGGAATGACCCGTCTGTG-3
() 5-CTGCCGTAGGCTCGTTGATG-3
CCND1, Hs. 523852 480 () 5-AGTGCGAGGAGGAGGTCTTC-3
() 5-AGCGTGTGAGGCGGTAGTAG-3
CCNG2, Hs. 13291 744 () 5-AGGGCTGAGTTTGATTGAGG-3
() 5-TAGCTGTTGTGGAGGTTCTG-3
ATF3, Hs. 460 302 () 5-CTCGGAAGTGAGTGCTTCTG-3
() 5-CCGTCTTCTCCTTCTTCTTG-3
-Actin, Hs. 520640 183 () 5-GACAACGGCTCCGGCATGTGGCA-3
() 5-TGAGGATGCCTCTCTTGCTCTG-3
TRPV1 Agonists, ER Stress, and Cell Death 831
phy/UV analysis (230 nm). See supplemental data for chemical anal-
ysis data. All other chemicals and reagents were purchased from
established suppliers.
Cell Culture. BEAS-2B human bronchial epithelial cells (CRL-
9609) were purchased from American Type Culture Collection
(Manassas, VA). TRPV1-overexpressing cells were generated as de-
scribed previously (Reilly et al., 2003). BEAS-2B and TRPV1-over-
expressing cells were cultured in LHC-9 media (BioSource Interna-
tional, Camarillo, CA). Normal human bronchial epithelial (NHBE)
cells, a primary cell line, were purchased from Cambrex Bio Science
Walkersville, Inc. (Walkersville, MD) and cultured in BEGM media.
Human embryonic kidney (HEK)-293 human embryonic kidney
(CRL-1573) and A549 human lung carcinoma (CCL-185) cells were
purchased from American Type Culture Collection and were cul-
tured in Dulbecco’s modified Eagle’s medium:F-12 containing 10%
fetal bovine serum (Hyclone Laboratories, Logan, UT). Culture
flasks for BEAS-2B and TRPV1-overexpressing BEAS-2B cells were
coated with LHC basal media fortified with 30 g/ml collagen, 10
g/ml fibronectin, and 10 g/ml bovine serum albumin. Cells were
maintained between 30 and 90% maximal density and were subcul-
tured every 2 to 4 days.
Fluorometric Calcium Flux Assays. TRPV1-overexpressing
cells were used to evaluate calcium flux. Flux in BEAS-2B, A549, and
NHBE cells was not detectable. Functional evidence provided here
and in previous studies (Reilly et al., 2003, 2005; Johansen et al.,
2006) demonstrates that the TRPV1-overexpressing cells model re-
sponses of BEAS-2B and other lung cells when treated with diverse
TRPV1 agonists, with the exceptions that TRPV1-dependent calcium
flux is quantifiable and dose responses for TRPV1 agonists are
shifted to lower concentrations. To assay calcium flux, TRPV1-over-
expressing cells were subcultured into 96-well culture plates and
grown to 90% maximal density. Cells were loaded with the fluoro-
genic calcium indicator Fluo-4-acetoxymethyl ester (2.5 M) (In-
vitrogen, Carlsbad, CA) for 90 min at room temperature (22°C) in
LHC-9 media containing 200 M sulfinpyrazone. Cells were washed
and incubated for an additional 20 min at room temperature to
permit methyl ester hydrolysis and activation of Fluo-4. Changes in
cellular fluorescence in response to agonist and antagonist treat-
ments were assessed microscopically on cell populations 1 min after
treatments using methods described previously (Reilly et al., 2005;
Johansen et al., 2006). ER calcium flux was evaluated by pretreating
cells with 2.5 M thapsigargin for 5 min followed by addition of 2.5
M nonivamide. Calcium flux due to cell surface TRPV1 activity was
assessed by treating cells with nonivamide in calcium-free media
containing 50 M EGTA and 250 M ruthenium red. Differences in
fluorescence responses observed between the treatments and con-
trols were used to assess the relative contribution of ER-bound and
cell surface TRPV1 in total calcium flux initiated by agonists. Data
are expressed as -fold change in fluorescence intensity.
Cytotoxicity Assays. Cells were subcultured into Multiwell
plates and allowed to reach 90% confluence. The cells were treated
for 24 h with various agonists and antagonists prepared in the
appropriate culture media without fetal bovine serum. Cell viability
was assessed using the Dojindo cell counting kit-8 (Dojindo Labora-
tories, Gaithersburg, MD), according to the supplier’s recommenda-
tions. Loss of cell monolayer integrity due to treatment with toxic
TRPV1 agonists was confirmed microscopically. Toxicity data are
expressed as the percentage of remaining viable cells relative to
untreated controls, calculated using the absorbance ratio of the
formazan dye product generated from the Dojindo reagent.
RT-PCR Analysis. Cells were subcultured into 25-cm2 cell cul-
ture flasks, grown to a density of 90%, and treated with TRPV1
agonists and antagonists. Total RNA was extracted from cells using
the RNeasy RNA isolation kit (QIAGEN, Valencia, CA), and 2.5 g of
total RNA was transcribed into cDNA using PolyT and Superscript
III (Invitrogen). cDNA corresponding to GADD153, GADD45,
Fig. 1. Chemical structures for the
TRPV1 agonists and antagonists used
in this study.
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ATF3, CCND1, CCNG2, BiP/GRP78, and -actin was amplified by
PCR from 1 l of the cDNA synthesis reaction using the primers
listed in Table 1 and GoTaq Green PCR Master Mix (Promega,
Madison, WI). The PCR program consisted of an initial 2 min incu-
bation at 94°C and 28 cycles of 94°C (30 s), 55°C (30 s), and 72°C (30
s). A final extension period of 10 min at 72°C followed. PCR products
were resolved on 1% SB agarose gels, and images were captured
using a Gel-Doc imaging system (Bio-Rad, Hercules, CA). Product
quantification was achieved by determining the band intensities for
each PCR product relative to -actin, the internal PCR control, using
the Gel Doc density analysis tools in the Quantity One software
(Bio-Rad). Experiments were reproduced a minimum of three times
on different passages of cells.
Cloning of ER Stress Gene cDNA. The full-length cDNA for
human GADD153, ATF3, EIF2, and ATF4 were amplified from
BEAS-2B cells using Phusion GC-rich PCR Super Mix (New England
Biolabs, Ipswich, MA). The following primers were used: GADD153
() 5-CACCATGGCAGCTGAGTCATTGCCTTTC-3 and () 5-
TGCTTGGTGCAGATTCACCATTC-3, ATF3 () 5-CACCATGATG-
CTTCAACACCCAG-3, and () 5-ATACTGAAGCTGCAGGCACTC-
3, EIF2 () 5-CACCATGCCGGGTCTAAGTTGTAG-3 and ()
5-ATCTTCAGCTTTGGCTTCCATTTC-3, and ATF4 () 5-CAC-
CATGACCGAAATGAGCTTCCTG-3 and () 5-GGGGACCCTTT-
TCTTCCCCCTTG-3. These primers incorporated a 5-CACC se-
quence immediately before the ATG start site to permit directional
cloning into the pcDNA3.1-V5/His6 mammalian expression vector
(Invitrogen) and eliminated the stop codon to allow for epitope tag-
ging with V5-His6. An expression plasmid for p58IPK (pcDNA1-
p58IPK) was generously provided by Dr. Michael G. Katze (University
of Washington, Seattle, WA). The pMaxGFP expression vector was
purchased from Amaxa Biosystems (Gaithersburg, MD). All clones
were sequence verified by comparison to the appropriate GenBank
sequences. Plasmids used in the transient transfection assays were
simultaneously purified using the QIAGEN Plasmid DNAMidi-Prep
kit and further purified using the GeneElute HP Plasmid Mini-Prep
kit (Sigma-Aldrich).
Site-Directed Mutagenesis. The GADD153-L134A/L141A
(Matsumoto et al., 1996) and EIF2-S52A (Srivastava et al., 1998)
dominant-negative mutants were constructed using the QuikChange
XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) and
the following primers: GADD153-L134A/L141A () 5-GGCAC-
AGGCAGCTGAAGAGAATGAACGGGCCAAGCAGG-3 and () 5-
CCTGCTTGGCCCGTTCATTCTCTTCAGCTGCCTGTGCC-3 and
EIF2S52A () 5-CTTCTTAGTGAATTAGCCAGAAGGCG-3 and
() 5-GGATACGCCTTCTGGCTAATTCACTA-3.
Transient Overexpression Assays and Stable Overexpress-
ing Cell Lines. A459 cells respond to TRPV1 agonists similar to
BEAS-2B, NHBE, and TRPV1-overexpressing cells, with the excep-
tion that they exhibit slightly reduced sensitivity to agonists due to
lower levels of TRPV1 expression (Reilly et al., 2003). A549 cells were
used as transfection hosts to evaluate the protoxic effects of ER
stress-induced gene products in lung cells, because they exhibited
reproducibility in transfection efficiency and limited toxicity due to
transfection reagents. Transfection efficiency typically reached
80% using A549 cells versus 5 to 10% with BEAS-2B cells, or
1% using NHBE cells. This level of transfection was necessary to
evaluate the effects of ER stress genes on cell populations. A549 cells
were subcultured into 48-well cell culture plates and grown to a
density of70 to 80%. Cells were washed with Opti-MEMmedia and
transfected for 18 h using Lipofectamine 2000 (Invitrogen) at a
ratio of 3:1 lipid/plasmid DNA. After transfection, cells were washed
with Opti-MEM and allowed to grow for an additional 24 h. Cell
viability was assessed as described above. All experiments were
performed in triplicate and were normalized to control cells trans-
fected with equal quantities of the pMaxGFP plasmid.
Stably overexpressing cell lines were generated by culturing
transfected A549 cells in media fortified with 600 g/ml G-418 (Ge-
neticin; Invitrogen) for 3 weeks. Resistant foci were isolated and
expanded in selective media. Individual clones were screened for
overexpression of the target genes by assaying for V5-His6 expres-
sion by RT-PCR and subsequently used for cytotoxicity screening.
Western Blotting. BEAS-2B cells were grown to 90% maximal
density in 25-cm2 flasks. Before treatment cells were cultured in
fresh media for 2 h. Cells were treated for 0, 1, 2, 4, and 8 h, rinsed
with phosphate-buffered saline, and immediately lysed on ice using
20 mM HEPES, pH 7.5, containing 150 mM NaCl, 1% Triton X-100,
1 mM EDTA, 10 mM sodium pyrophosphate, 100 mM sodium fluo-
ride, 17.5 mM -glycerophosphate, 1 mM phenylmethylsulfonyl flu-
oride, 4 mg/ml aprotinin, and 2 mg/ml pepstatin A. The lysates were
clarified by centrifugation at 20,000g for 15 min at 4°C, and the
concentration of protein was determined using the BCA protein
assay (Pierce Chemical, Rockford, IL). Fifty micrograms of soluble
protein from each sample then was resolved on a 10% NuPAGE gel
(Invitrogen) and subsequently transferred to polyvinylidene difluo-
ride membrane. The blots were probed for EIF2-P using a rabbit
polyclonal IgG fraction specific to EIF2-pS52 (BioSource, Interna-
tional) according to supplier protocols. GADD153 expression was
determined using an anti-GADD153 antibody from Biolegend (San
Diego, CA) and the protocol provided by the supplier.
Statistical Analysis. Statistical testing used the paired t tests
and ANOVA with post hoc testing using Dunnett’s test to determine
significance. A 95% confidence interval was used as the limit for
significance. Specific details on statistical analyses are presented in
the figure legends.
Results
Treatment of TRPV1-overexpressing cells with 2.5 M
nonivamide produced marked increases in cytosolic calcium
due to release of calcium from ER stores (Fig. 2A). EGTA and
ruthenium red cotreatment had little to no effect on calcium
flux, but cotreatment with LJO-328 or prior depletion of ER
calcium stores with thapsigargin completely prevented cal-
cium flux. n-Benzylnonanamide failed to elicit ER calcium
release at 2.5 M (Fig. 2A) or at concentrations up to 25 M
(data not shown). Treatment of TRPV1-overexpressing cells
with 1 M nonivamide caused an approximate 50% loss in
cell viability after a 24-h period (Fig. 2B). Cell death corre-
sponded to a loss of monolayer consistency (data not shown)
and was inhibited by LJO-328 cotreatment, but not by EGTA
and ruthenium red. n-Benzylnonanamide did not cause cell
death, consistent with a lack of TRPV1 activation.
Analysis of collective genetic responses in TRPV1-overex-
pressing and BEAS-2B cells exposed to 1 and 100 M (LC50
concentrations) nonivamide, respectively, for 4 h, in the pres-
ence or absence of LJO-328, by microarray yielded prelimi-
nary insight into cellular processes that constituted the cell
death process (see Supplemental Data, explanation of mi-
croarray data and microarray data). Increased expression of
GADD153, GADD45, ATF3, CCNG2, and BiP/GRP78
mRNA and a decrease in CCND1 mRNA were observed, and
these responses were validated by RT-PCR (Fig. 3A). Co-
treatment of cells with the TRPV1 antagonist LJO-328 pre-
vented changes in gene expression, whereas little to no inhi-
bition was observed using EGTA and ruthenium red (Fig.
3A). Treatment of BEAS-2B cells with the prototypical ER
stress-inducing agents thapsigargin and DTT produced sim-
ilar changes in the expression of GADD153, GADD45,
ATF3, CCND1, CCNG3, and BiP/GRP78 (Fig. 3B) mRNA.
BEAS-2B cells treated with 100 and 200 M nonivamide
also exhibited a shift in the relative amount of EIF2-P and
an increase in the expression of GADD153 mRNA and pro-
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tein (Fig. 4, A–C). EIF2 phosphorylation and GADD153
expression was inhibited by LJO-328, but not by EGTA and
ruthenium red (Fig. 4A). The kinetic and dose-dependent
features of GADD153 induction and EIF2-P accumulation
paralleled cytotoxicity (Fig. 4, A–C). The highest levels of
EIF2 phosphorylation and GADD153 protein were detected
at 8 h with 200 M nonivamide. For GADD153, increases
in mRNA in BEAS-2B cells was maximal at 4 h and oc-
curred at concentrations 150 M. Similar responses were
observed using the TRPV1-overexpressing cells, but maximal
increases in protein and mRNA were observed with a dose of
1 to 2 M (data not shown).
Transient overexpression of GADD153 in A549 cells pro-
duced an approximate 50% loss in cell viability relative to
pMaxGFP-transfected control cells in the absence of cytotoxic
TRPV1 agonists (Fig. 5A). Transient overexpression of ATF4,
which stimulates GADD153 transcription, also produced
20% cell death. GADD153-L134A/L141A, ATF3, or p58IPK
were not cytotoxic. Transient cotransfection of A549 cells
with ATF3 and GFP (10:1) yielded a high proportion of viable
GFP-expressing cells 48 h after the transfection procedure
(Fig. 5B). No ethidium bromide (EtBr)-stained nuclei were
observed in these cells, indicating cellular integrity. Con-
versely, very few cells transfected with GADD153 and GFP
(10:1) survived, whereas those that remained attached to the
culture dish exhibited intense nuclear staining with EtBr.
These data were consistent with a loss of cell viability, cell
membrane integrity, and oncotic cell death, as reported pre-
viously for BEAS-2B and A549 cells treated with capsaicin
(Reilly et al., 2003).
Inhibition of cytotoxicity using dominant-negative forms of
EIF2 (EIF2-S52A) and GADD153 (GADD153-L134A/
L141A) was also evaluated (Fig. 6). Figure 6A shows that
both the EIF2-S52A- and GADD153-L134A/L141A-overex-
pressing A549 cells were less susceptible to cytotoxicity by
nonivamide. Likewise, the addition of salubrinal to treat-
ment solutions containing 1 or 100 M nonivamide inhibited
Fig. 2. Relationship between calcium flux (A) and cell death (B) in
TRPV1-overexpressing cells. Cells were assayed for calcium flux and cell
death, as described underMaterials and Methods. A, treatments were 2.5
Mnonivamide, nonivamide EGTA, and ruthenium red (50 250 M),
nonivamide following 5-min pretreatment with 2.5 M thapsigargin, 2.5
M n-benzylnonanamide, and nonivamide  20 M LJO-328. Identical
treatments were used in B with the exception that ruthenium red and
EGTA were used separately. , p  0.025, paired t test; n  3.
Fig. 3. Modulation of ER stress response gene expression in BEAS-2B
cells treated with nonivamide (A) and prototypical ER stress-inducing
agents (B). All treatments were performed for 4 h at 37°C in six-well
plates using LHC-9 as the vehicle. A, BEAS-2B cells treated with fresh
media (Ct), 100 M nonivamide (N), nonivamide and 30 M LJO-328
(NL), or nonivamide and EGTA (50 M) and ruthenium red (250 M)
(NER). Total RNA was extracted for analysis of gene expression, as
described under Materials and Methods. Images showing changes in the
expression of GADD153, GADD45, ATF3, CCND1, CCNG2, and BiP/
GRP78 as well as quantitative results for changes in gene expression (bar
graph) are shown. All data are normalized to -actin, the smaller PCR
product shown for each image panel. White bars represent untreated
control cells, light gray bars represent cells treated with 100 M noniv-
amide for 4 h at 37°C, medium gray bars represent cells treated with
nonivamide and 20 M LJO-328, and black bars represent cells treated
with nonivamide and EGTA  ruthenium red (50  250 M). B,
BEAS-2B cells were treated with Ct, thapsigargin (2.5 M), DTT (1 mM),
or H2O2 (1 mM), processed, and assayed by RT-PCR, as described for A.
White bars represent untreated cells, light gray bars represent cells
treated with thapsigargin, medium gray bars represent cells treated with
DTT, and black bars represent cells treated with H2O2. , significant
changes in expression relative to control cells; #, statistically significant
changes relative to nonivamide treatment (ANOVA, 95% confidence in-
terval; n  3).
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cell death in TRPV1-overexpressing and BEAS-2B cells with
a maximal effect between 2.5 and 5 M (Fig. 6B). Salubrinal
inhibits EIF2K3-induced cytotoxicity (Lu et al., 2004; Boyce
et al., 2005)
Induction of the proapoptotic/oncotic ER stress-induced
gene GADD153 was also compared in TRPV1-overexpress-
ing, BEAS-2B, A549, and NHBE lung cells as well as HEK-
293 cells (Table 2). All four lung cell types express TRPV1,
but HEK-293 cells do not. Significant (6- to 8-fold) GADD153
mRNA induction was observed following 4-h treatment of
BEAS-2B, TRPV1-overexpressing, A549, and NHBE cells
with LC50 concentrations of nonivamide, resiniferatoxin, and
anandamide, but not with n-benzylnonanamide. Interest-
ingly, n-benzylnonanamide inhibited cell death caused by
nonivamide in the TRPV1-overexpressing cells at concentra-
tion ratios 5:1 (data not shown). Induction of GADD153
transcription was attenuated by LJO-328 in all cells types
exhibiting a response as well as by 5-iodo-RTX in the TRPV1-
overexpressing line. GADD153 induction was not observed in
HEK-293 cells treated with nonivamide or resiniferatoxin.
Discussion
Previous studies of TRPV1 and the effects of its agonists on
cultured lung cells and in animal models of airway injury
support the hypothesis that TRPV1 is a mediator of lung
injury and inflammation (Reilly et al., 2003, 2005; Vargaftig
and Singer, 2003; Li et al., 2005; Trevisani et al., 2005;
Bhatia et al., 2006; Geppetti et al., 2006). However, precise
molecular mechanisms of cell death have not been estab-
lished.
Quantitation of calcium flux in TRPV1-overexpressing
cells demonstrated that 85 to 90% of functional TRPV1 ex-
isted in the ER membrane (Fig. 2A). Selective inhibitors of
TRPV1 and treatments that reduced the passage of calcium
ions from extracellular sources into cells (Fig. 2, A and B)
confirmed previous data demonstrating a correlation be-
tween ER calcium release and cytotoxicity in TRPV1-overex-
pressing cells (Reilly et al., 2005). Although calcium flux was
not detected in BEAS-2B, NHBE, or A549 cells, results pre-
sented here demonstrate that the TRPV1-overexpressing
cells model the TRPV1 agonist-induced effects in these cell
types.
cDNA microarray analysis (see supplemental data, expla-
nation of microarray data and microarray data) demon-
strated that TRPV1 activation was associated with changes
in the expression of several prototypical ER stress genes in
lung cells. Comparisons between gene expression changes
elicited by nonivamide in the presence and absence of LJO-
328 and EGTA/ruthenium red (Fig. 3A) and changes elicited
by the prototypical ER stress inducing-agents thapsigargin
and DTT (Fig. 3B) support our conclusion that TRPV1 acti-
vation causes ER stress. Furthermore, ER stress proceeded
via pathways similar to those activated by thapsigargin and
DTT (Schroder and Kaufman, 2005).
ER stress responses are compensatory responses. Up-reg-
ulation of specific gene products through dedicated signaling
pathways, coupled with cell cycle arrest and a temporary halt
of general transcription and translation, are coordinated pro-
cesses that have evolved to help cells overcome inefficiencies
in protein processing (Schroder and Kaufman, 2005). Alter-
ations in ER processing efficiency occur with nutrient depri-
vation, viral infection, disruption of cellular redox state,
changes in ER folding environment (e.g., alterations in cal-
cium homeostasis, redox state), expression of unstable poly-
morphic variant proteins, and toxicant exposures (Cribb et
al., 2005; Schroder and Kaufman, 2005). If cells cannot com-
pensate for a specific stress, they die.
ER stress-induced cell death has been primarily attributed
to the expression of GADD153 following EIF2K3 activation
(Matsumoto et al., 1996; McCullough et al., 2001; Oyadomari
and Mori, 2004). GADD153 inhibits cell proliferation by re-
ducing the expression of CCND1, and it causes cell death by
sequestering the antiapoptotic Bcl-2 protein and inhibiting
nuclear factor-B and Akt/protein kinase B-mediated cyto-
Fig. 4. Concentration- and time-dependent changes in GADD153 expres-
sion, EIF2 phosphorylation, and cell viability in BEAS-2B cells. A,
Western blot analysis showing the time- and dose-dependent changes in
GADD153 expression and EIF2 phosphorylation in BEAS-2B cells
treated with 100 M nonivamide (N1), 200 M nonivamide (N2), 100 M
nonivamide plus 30 M LJO-328 (N1L), or 100 M nonivamide plus 50
MEGTA and 250 M ruthenium red (N1ER). B, dose-response relation-
ship between cell death and GADD153 induction. Dose-response cytotox-
icity curve for nonivamide in BEAS-2B cells (solid circles, solid line) and
induction of GADD153 (open circles, dashed line; right axis). C, time-
dependent loss of cell viability and increased expression of GADD153
mRNA. BEAS-2B cells (solid squares, cell viability; open squares,
GADD153 expression) were treated with 100 M nonivamide. All data
are relative to control cells treated in an identical manner using media
only (n  3).
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protective processes (McCullough et al., 2001; Hu et al., 2004;
Hyoda et al., 2006). The balance between cell death and
survival ultimately depends upon the level of GADD153 ex-
pression and the coexpression of other pro- and anticytotoxic
gene products that participate in ER stress responses.
Treatment of BEAS-2B cells with nonivamide promoted
the phosphorylation of EIF2 at serine 52 (Fig. 4A). This was
indicative of EIF2K3 activation. EIF2 phosphorylation
was associated with increased expression of GADD153 ex-
pression (Figs. 3A and 4, A and B). Increased concentrations
of EIF2-P and GADD153 correlated with the onset of cell
death in BEAS-2B cells, as determined using dose- and tem-
poral-response correlations with protein and mRNA (Fig. 4,
A–C). These trends were reproduced using the TRPV1-over-
expressing line. EIF2 phosphorylation and GADD153 ex-
pression were attenuated by LJO-328, but not by EGTA or
ruthenium red. n-Benzylnonanamide, a pharmacologically
inactive nonivamide analog, did not promote ER calcium
release or induce GADD153 expression in BEAS-2B or any
other cells tested, and it was nontoxic at concentrations equal
to or in 2-fold excess of nonivamide (Fig. 2, A and B; Table 2).
These data support our conclusion that TRPV1 activation
promotes cytotoxicity via activation of EIF2K3, phosphory-
lation of EIF2, and expression of GADD153.
To substantiate the role of GADD153 in cell death, we
cloned this gene and transiently transfected A549 cells with
the expression construct. Performing transient transfection
studies in the BEAS-2B and NHBE cells were hampered by
variable transfection efficiency and high levels of toxicity due
to transfection reagents. As such, we used A549 cells as the
model for these experiments. We have previously shown that
A549 cells respond to TRPV1-agonists similar to BEAS-2B
cells (Reilly et al., 2003). Cells transfected with GADD153
exhibited reduced viability due to loss of cells from the cul-
ture wells (Fig. 5, A and B). Cytotoxicity and cell loss relative
to controls were not observed with GADD153-L134A/L141A,
ATF3, or p58IPK, but toxicity was observed with ATF4. These
results were consistent with the established roles of these
proteins (Schroder and Kaufman, 2005). Specifically, ATF3
and p58IPK limit ER stress responses by inhibiting ATF4-
Fig. 5. A, viability of A549 cells transiently transfected with ER stress-induced genes. Cells were subcultured into 48-well plates and transfected for
18 h with mammalian expression plasmids harboring cDNA for EGFP, GADD153, ATF3, ATF4, and p58IPK. After a 24-h recovery period, cell viability
was determined. , statistically significant decrease in viability (ANOVA, 95% confidence interval; n 3). B, bright field and fluorescence micrographs
of A549 cells cotransfected with ATF3  EGFP and GADD153  EGFP (10:1 target gene plasmid:pMax-GFP). Light, bright field image; GFP,
fluorescence image using a filter set to image GFP expression; EtBr, fluorescence image using a filter set to visualize propidium iodide- or ethidium
bromide-stained cell nuclei. After transfection and a 24-h recovery period, cells were sequentially imaged to assess the survival of GFP-transfected
cells and dead/damaged cells (EtBr) resulting from transfection of either ATF3 (control) or GADD153. In total, 25 ng of plasmid DNA was used
for each transfection. , p  0.025, paired t tests; n  3.
Fig. 6. A, dose-response cytotoxicity curves for A549 (open triangles) and
stably overexpressing cell lines harboring the dominant-negative EIF2-
S52A (open squares) and GADD153-L134A/L141A (open circles) genes. B,
inhibition of cell death in BEAS-2B and TRPV1-overexpressing cells
using salubrinal. Cells were treated with 1 M nonivamide (TRPV1-
overexpressing cells) or 100 M nonivamide (BEAS-2B cells) in the pres-
ence and absence of salubrinal for 24 h at 37°C in LHC-9 media. Circles,
TRPV1-overexpressing cells; triangles, BEAS-2B cells treated with noni-
vamide and increasing concentrations of salubrinal. Data representing
changes in viability due to treatment of BEAS-2B and TRPV1-overex-
pressing cells with salubrinal only are represented as squares and dots,
respectively. Cell viability was determined as described under Materials
and Methods. Data (n  6) are relative to untreated controls.
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dependent gene transcription and the phosphorylation of
EIF2 by EIF2K3, respectively. Conversely, ATF4 pro-
motes GADD153 transcription, and GADD153 is procyto-
toxic. Additional support for GADD153 as the ultimate me-
diator of cytotoxicity was obtained by treating A549 cells that
stably overexpressed the GADD153-L134A/L141A dominant-
negative mutant (Matsumoto et al., 1996). Overexpression of
GADD153-L134A/L141A markedly reduced cytotoxicity
caused by nonivamide (Fig. 6A). Data in Figs. 5 and 6 imply
that GADD153 was the primary cause of cytotoxicity in lung
cells treated with TRPV1 agonists.
The effects of modifying the EIF2K3/EIF2 signaling
were also evaluated. Two approaches were used: stable over-
expression of the EIF2-S52A dominant-negative mutant in
A549 cells (Srivastava et al., 1998) and pharmacological sta-
bilization of EIF2-P in BEAS-2B and TRPV1-overexpress-
ing cells using salubrinal (Boyce et al., 2005). Interestingly,
squelching of EIF2 phosphorylation (Fig. 6A) and inhibition
of EIF2 dephosphorylation (Fig. 6B) protected cells from
toxicity. Initially, these data seemed contradictory, but liter-
ature supports a dual role for EIF2-P in regulating cell
survival and death during ER stress. Thus, the results in Fig.
6, A and B, highlight this dual effect of the EIF2K3/EIF2
pathway. However, the molecular basis for these antithetical
responses remains enigmatic.
We also investigated whether ER stress represented a
common mechanism of cytotoxicity for structurally diverse
TRPV1 agonists. Table 2 shows that transcriptional activa-
tion of GADD153 occurred in BEAS-2B, A549, NHBE, and
TRPV1-overexpressing cells treated with LD50 concentra-
tions of nonivamide, resiniferatoxin, and anandamide. As
predicted, TRPV1 agonists failed to induce GADD153 expres-
sion in the TRPV1-null HEK293 cell line (Table 2). Likewise,
n-benzylnonanamide failed to elicit GADD153 expression,
confirming the direct link between TRPV1 activation,
GADD153 expression, and cell death. This conclusion was
also supported by the inhibition of GADD153 expression by
LJO-328 and 5-iodo-RTX (Table 2). The inability of 5-iodo-
RTX to completely inhibit GADD153 expression in the
BEAS-2B cell line was consistent with our previous findings
that 5-iodo-RTX (like capsazepine) causes cytotoxicity at el-
evated concentrations (Reilly et al., 2003, 2005).
Collectively, the results presented by this study support
the following mechanism of cytotoxicity for TRPV1-agonists
in lung (and possibly other) cells. First, activation of intra-
cellular TRPV1 leads to a decrease in ER calcium content, an
accumulation of unfolded/partially folded proteins in the
ER lumen, and an overall decrease in protein processing
efficiency. As a result, EIF2K3 is activated resulting in
the phosphorylation of EIF2 and an increase in the expres-
sion of ATF4, GADD153, and other ER stress-related genes.
Ultimately, increased transcription and expression of
GADD153 causes cell death.
The translational facets of the results presented in this
study are 2-fold. First, the near uniform response elicited by
structurally diverse TRPV1 agonists in all four lung cell
types suggests that this mechanism of toxicity is applicable
to many other TRPV1 agonists. Specifically, environmental
TRPV1 agonists that promote lung inflammation and injury
(e.g., particle pollutants) and endogenous TRPV1 agonists
(e.g., leukotrienes, H2S) that are produced during inflamma-
tion or infection may also cause lung cell death and tissue
damage via the EIF2K3-dependent ER stress pathway. As
such, future clinical research targeting TRPV1 and/or the
EIF2K3-dependent ER stress pathways may prove benefi-
cial in the treatment and/or prevention diverse respiratory
maladies. Second, our results indicate that the effects of a
TRPV1 ligand on a cell will depend upon both the relative
subcellular distribution of TRPV1 and the relative perme-
ability of the ligand. Hence, it must be stressed that the
subcellular location of TRPV1 should be established and mul-
tiple TRPV1 agonists and antagonists (preferably not capsaz-
epine) should be used in future research studies evaluating
the role of TRPV1 in specific biological outcomes. Although
we have not specifically tested whether cell-impermeable
agonists of TRPV1 (e.g., pH or environmental particle pollut-
ants) exhibit different mechanisms of cytotoxicity, evidence
supports this hypothesis. Specifically, inhibition of the cell
surface TRPV1 in lung cells has no effect on cytotoxicity by
TRPV1 agonists, despite inhibition of proinflammatory cyto-
kine synthesis (Reilly et al., 2005), and sensory neurons,
which primarily express TRPV1 on the cell surface, are pro-
tected against cytotoxicity by inhibiting cellular influx of
calcium (Wood et al., 1988).
Overall, these results provide novel insight into mecha-
nisms by which diverse exogenous and endogenous TRPV1
agonists affect lung cell physiology. These findings provide
fundamental knowledge that will facilitate future basic sci-
TABLE 2
Induction of GADD153 expression by multiple TRPV1 agonists and inhibition by antagonists in various cell lines
Treatment (4 h)
GADD153 Induction (-Fold Control)
TRPV1-
Overexpressing BEAS-2B NHBE A549 HEK-293
Nonivamide, 1 M 8.1  0.8*
Nonivamide, 100 M 7.9  0.5* 6.0  0.4* 5.5  0.3* 0.88  0.07
Nonivamide, 200 M 1.19  0.06
Resiniferatoxin, 0.01 M 7.9  0.8*
Resiniferatoxin, 7.5 M 6.4  0.8* 6.3  0.3* 4.8  0.4* 0.77  0.08
Anandamide, 12.5 M 7.4  0.6*
Anandamide, 25 M 6.9  0.5* 3.3  0.2*
n-Benzylnonanamide, 1 M 1.3  0.2
n-Benzylnonanamide, 100 M 2.2  0.3 2.6  0.2* 0.65  0.07 0.78  0.04
Capsaicin, 1 M  5-iodo-RTX, 1 M 0.6  0.4
Capsaicin, 100 M  5-iodo-RTX, 30 M 10.4  0.9* 4.2  0.4*
Capsaicin, 1 M  LJO-328, 20 M 1.34  0.03
Capsaicin, 100 M  LJO-328, 50 M 1.4  0.2 1.0  0.1 0.75  0.09 0.84  0.07
* Statistically significant increase relative to control (p  0.05, t test; n  3).
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ence and clinical research on TRPV1 in an array of physio-
logical and pharmacological models, including models of
acute lung injury and inflammatory lung injury.
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STRUCTURE ACTIVITY RELATIONSHIPS FOR CAPSAICIN  
ANALOGUES AND TRPV1-MEDIATED HUMAN LUNG  




Capsaicinoid compounds activate transient receptor potential vanilloid-1 
(TRPV1).  Activation of intracellular TRPV1 in human lung cells causes calcium efflux 
from the endoplasmic reticulum (ER), activation of the unfolded protein response/ER 
stress, and cell death via increased expression of pro-apoptotic GADD153. In this study, 
variants of capsaicin and its analogue nonivamide were synthesized and used to probe the 
relationship between TRPV1 receptor binding, activation, ER calcium release, changes in 
GADD153 expression, and cell death in TRPV1-overexpressing BEAS-2B, BEAS-2B, 
and primary NHBE lung cells. The vanilloid ring pharmacophore of capsaicin is 3-
methoxy-4-hydroxybenzylamide.  Removal, substitution, methylation, or repositioning of 
the 3-MEO- or 4-OH group on the vanilloid ring pharmacophore of nonivamide markedly 
reduced analogue potency and toxicity using calcium flux, GADD153 induction, and 
cytotoxicity as quantitative measures. Molecular modeling of binding interactions 
between TRPV1 and the various analogues verified that the inactive analogues do not 
form ‘productive’ ligand receptor complexes. Demethylation of the 3-MeO- group to 
produce the n-(3,4-dihydroxybenzyl)nonanamide analogue slightly reduced cytotoxicity 




2B cells. This indicates a decrease in TRPV1-binding and activation, and co-activation of 
non-TRPV1-mediated cell death processes, presumably involving redox cycling of the 
catechol and increased production of reactive oxygen species. This conclusion was 
confirmed by an attenuation of cell death by n-acetylcysteine (NAC) co-treatment. All 
three cell types responded similarly to the analogues, but NHBE cells appeared to have 
greater capacity to detoxify the catechol analogue. This study further defines how 
capsaicinoids interact with TRPV1 to alter cellular function, and provide strong support 
for TRPV1-mediated ER stress as an important mechanism of cell death in lung cells 
exposed to capsaicinoid compounds and other TRPV1 agonists.  
3.2 Introduction 
 
The capsaicin receptor, TRPV1, is a popular pharmacological target due to its 
functional diversity and many hypothesized roles in pathology and disease (1, 2). 
Endogenous and exogenous noxious stimuli activate TRPV1, including heat, acidic pH, 
and a variety of chemical irritants (2-4). The prototypical agonist of TRPV1 is capsaicin 
(N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide), the pungent 
compound in chili peppers that elicits a burning sensation upon contact.  
TRPV1 is functionally expressed in sensory (C- and A!-fibers) neurons and a 
variety of non-neuronal cell types. Activation of TRPV1-expressing sensory nerves in the 
airways elicits cough, dyspnea, and neurogenic inflammation characterized by plasma 
extravasation and edema. In lung epithelial cells, the physiological functions of TRPV1 
remain poorly understood. Accumulating evidence suggests that TRPV1 helps regulate 
host defense/innate immunity through regulation of proinflammatory responses 




genes following exposure to injurious agents, including TRPV1 agonists (15-17). It is 
proposed that the influx of neutrophils into the lung following exposure to TRPV1 
agonists is mediated, in part, by TRPV1 activation in epithelial cells.  
 Rats exposed to capsaicin aerosols also exhibit alveolar damage and significant 
cell damage and cell loss in the conducting airways (18). In cultured human lung 
epithelial cells, capsaicin and structurally related compounds activate TRPV1, leading to 
dose- and time-dependent cytokine release, ER stress, and cell death (16, 18, 19). 
Increases in IL-6 and IL-8 are predominantly associated with activation of cell surface 
TRPV1, while activation of ER associated TRPV1 causes ER stress, leading to activation 
of the PERK pathway, GADD153 induction, and cell death (15, 16, 18, 19). Blocking 
TRPV1 activation with cell-permeable antagonists such as LJO-328 ameliorates ER 
stress, but inhibition of calcium influx via cell surface TRPV1 only attenuates cytokine 
gene induction, not lung cell death. TRPV1 antagonists do not protect cells with low 
TRPV1 expression from cytotoxicity, despite attenuating ER stress (16, 18, 19). 
Previous structure-activity relationships determined that the essential structural 
properties of capsaicin for TRPV1 activation required substituents in specific positions 
on the aromatic ring, presence of the amide bond, and a narrow range of carbons in the 
hydrophobic hydrocarbon ‘tail’ (5-7). For the A-region of nonivamide (vanilloid ring), 
compounds with the parent capsaicin structure of 3-methoxy-4-hydroxybenzyl were the 
most potent agonists. Substitutions at positions 2, 5 and 6 on the ring reduced or ablated 
activity. If 4-OH was removed, activity was lost; alkylation of 4-OH also reduced or 
removed activity. Removal of or changing the substituent at the 3-position reduced or 




catechol compounds were equipotent in vitro but were not as potent in a functional 
analgesia model (7). For the B-region of nonivamide (amide bond), features required for 
activity were sp3 hybridization of the nitrogen, potential for hydrogen bonding, and the 
presence of a single bridging carbon to the vanilloid ring. Thiourea analogues were the 
most potent (6).!For the C-region of nonivamide (hydrophobic tail), the most important 
features were length (8-12 carbons) and hydrophobicity, as substitution with polar groups 
decreased potency (5). Use of these criteria also led to the synthesis and characterization 
of capsazepine, the first selective antagonist of TRPV1 (8). More recent site-directed 
mutagenesis studies of TRPV1 and molecular modeling of the identified capsaicin 
binding site have verified the necessity of the structural features first described by 
Walpole and Wrigglesworth (9-14). 
 For this study, a series of capsaicin/nonivamide analogues with modified vanilloid 
ring pharmacophores were synthesized to assess and differentiate between TRPV1-
mediated and nonspecific cell death in lung cell culture models and for future use in 
studies of TRPV1-mediated lung injury in animal models.  The ability of these modified 
capsaicinoids to bind and activate TRPV1, induce ER stress, and cause cell death, as well 
as the ability of these chemicals to function as antagonists of TRPV1, was investigated.  
3.3 Methods 
3.3.1 Chemicals 
Nonivamide (n-vanillylnonanamide or n-(4-hydroxy-3- 
methoxybenzyl)nonanamide), sulfinpyrazone, ionomycin, n-acetylcysteine, DMSO, 3-




nonanoyl chloride, methanol, sodium methoxide, ethyl acetate and hexane were 
purchased from Sigma-Aldrich (St. Louis, MO). Nonivamide and capsaicin have 
indistinguishable toxicity profiles in the human lung cells used in this study, thus 
nonivamide was used as the prototype TRPV1 agonist. LJO-328 was provided by Dr. 
Jeewoo Lee (Seoul National University, Seoul, Korea).  PCR primers for TRPV1, 
GADD153 and "2M were synthesized by the University of Utah Core Facilities (Salt 
Lake City, UT).  
3.3.2 Synthesis of Capsaicinoid Analogues 
n-Benzylnonanamide was synthesized as described previously (19). n-(3-hydroxy-
4-methoxybenzyl)nonanamide and n-(3,4-dihydroxybenzyl)nonanamide were 
synthesized by reacting 3-hydroxy-4-methoxybenzylamine-HCl and 3,4-
dihydroxybenzylamine-HBr with a 5-fold molar excess of nonanoyl chloride in 0.1N 
NaOH at room temperature.  The precipitates were collected by vacuum filtration over a 
paper filter, rinsed with saturated sodium carbonate and water, and air-dried.  The crude 
acylated products were dissolved in dry methanol and reacted with 0.5 M sodium 
methoxide at room temperature under argon for 2 hours.  The mixture was neutralized 
with amberlite IR120(H+), filtered, dried under vacuum, and the crude product was 
purified over a silica gel column eluted with ethyl acetate:hexane (1:5 v/v).  Product 
purity (>95%) and structure were determined by HPLC with UV detection at 230 nm, 
LC/MS2, and [1H]NMR.   
3.3.3 Cell Culture 
Immortalized human bronchial epithelial cells (BEAS-2B) were purchased from 




2B (TRPV1-OE) cells were generated as described previously (18).  BEAS-2B and 
TRPV1-OE cells were cultured in LHC-9 media (Invitrogen, Carlsbad, CA). Normal 
Human Bronchial Epithelial (NHBE) cells, a primary cell line, were purchased from 
Lonza (Walkersville, MD) and cultured in BEGM media.  Culture flasks for NHBE, 
BEAS-2B and TRPV1-OE cells were coated with LHC basal media fortified with 30 
µg/mL collagen, 10 µg/mL fibronectin, and 10 µg/mL bovine serum albumin.  Cells were 
maintained between 30 to 90% maximum density and were subcultured every 2-4 days 
depending on cell growth rates. 
3.3.4 Cytotoxicity/Dose Response Assays 
Cells were subcultured into 96-well plates and grown to ~90% confluence.  Cells 
were treated for 24 hours at 37ºC with increasing concentrations of chemical.  Treatment 
solutions were prepared using LHC-9 media for BEAS-2B and TRPV1-OE cells 
(Invitrogen, Carlsbad, CA).  For NHBE cells, agonist and antagonists were prepared in 
Opti-MEM I Reduced Serum Medium (Invitrogen, Carlsbad, CA) without fetal bovine 
serum.  Cell treatment solutions contained # 0.5% DMSO.  Cell viability was assessed 
using the Dojindo cell counting kit-8 (Dojindo Laboratories, Gaithersburg MD), 
according to supplier’s recommendations. Toxicity data are expressed as the percentage 
of viable cells relative to untreated controls, calculated using the absorbance at 450 nm 
minus the absorbance at 630 nm. 
3.3.5 Fluorometric Calcium Assays 
TRPV1-OE cells were used to evaluate calcium flux as a consequence of TRPV1 
activation. TRPV1-OE cells were sub-cultured into 96-well culture plates and grown to 




indicator Fluo-4-acetoxymethyl ester (Fluo-4 AM, 2.5 µM) (Invitrogen, Carlsbad, CA) 
for 60 minutes at room temperature (about 22º C), in the presence of 200 µM 
sulfinpyrazone in LHC-9 media.  Cells were washed twice and incubated at room 
temperature for an additional 20 minutes in sulfinpyrazone containing media to permit 
methyl ester hydrolysis and activation of Fluo-4 in cells.  Changes in cellular 
fluorescence in response to agonist and antagonist treatments were measured using a 
NOVOStar plate reader (BMG Labtech, Germany) with excitation at 485 nm and 
emission at 520 nm. Baseline fluorescence readings were subtracted from the 
fluorescence measured, and each treatment was performed in triplicate.  Ionomycin (10 
$M) produces maximum calcium movement into cells and was used as a positive control 
to normalize responses. Data in Table 3.1 are expressed as percent of ionomycin 
fluorescence ± standard deviation. 
3.3.6 Quantitative Real-Time PCR Analysis of Gene Expression 
Cells were subcultured into 6-well cell culture plates and grown to ~90% density.  
Cells were then treated with TRPV1 agonists and antagonists for 4 hours at 37ºC to 
determine GADD153 induction.  Total RNA was extracted from cells using the 
Invitrogen PureLink Micro-to-Midi Total RNA Purification System (Invitrogen, 
Carlsbad, CA), and 1 µg of the total RNA was transcribed into cDNA using Superscript 
III (Invitrogen, Carlsbad, CA). cDNA was diluted 1:100 in filter-sterilized Milli-Q H2O 
for all samples.  cDNA was amplified by PCR using RT2 SYBR Green qPCR Master Mix 
from SABiosciences (Frederick, MD) following manufacturer instructions in 25 µL 
reaction volumes on a Chromo 4 Real Time Detection System (Bio-Rad, Hercules, CA) 




minute incubation at 95ºC, followed by 40 cycles of 95ºC for 15 seconds, 55ºC for 30 
seconds, then 72ºC for 30 seconds. Experiments were performed in triplicate with a copy 
number standard curve for both the housekeeping gene ("-2 macroglobulin, "2M) and the 
genes of interest. Primer sequences for human "2M were:  
sense, 5’ –GATGAGTATGCCTGCCGTGTG – 3’; 
antisense, 5’ –CAATCCAAATGCGGCATCT – 3’. Primer sequences for human TRPV1 
were: sense, 5’- CTGCGGACCCACTCCAAAA-3’; 
antisense, 5’-CCTCGTGAGGGCAATCCAC-3’. Primer sequences for human 
GADD153 were: sense, 5’-AGAACCAGGAAACGGAAACAGA-3’;  
antisense 5’-TCTCCTTCATGCGCTGCTTT-3’. 
3.3.7 Molecular Modeling 
Chemical structures of capsaicin and capsaicinoid analogues were optimized 
using Gaussian03 software. Structures were then docked into a constrained PDB structure 
of TRPV1 transmembrane helices 3 and 4 (10) using AutoDock software.  The most 
highly populated energy cluster conformations of the docked structures were visualized 
in Chimera.  
3.3.8 Statistical Analysis 
Statistical analysis was performed using 95% confidence intervals as the limit for 
significance with p< 0.05%.  All results are represented as mean ± standard error of the 
mean unless otherwise indicated. For comparisons of two groups, unpaired student’s t-
test was used for statistical analysis. To compare more than two groups, one-way 
ANOVA analysis was performed with Newman-Keuls Multiple Comparison Test post-




using GraphPad Prism version 4.02 for Windows (GraphPad Software, San Diego, 
California, www.graphpad.com).  
3.4 Results 
A series of capsaicinoid analogues were synthesized to probe the relationship 
between TRPV1 binding, activation, ER stress and cell death. Structural attributes of 
each analogue are presented in Figure 3.1.  
TRPV1 transcription was quantified using RT-PCR in TRPV1-OE, BEAS-2B, 
and NHBE cells (Figure 3.2). TRPV1-OE cells expressed approximately 10 times more 
copies of TRPV1 mRNA than BEAS-2B cells, and approximately 45 times more copies 
than NHBE cells, using "2M as a normalization factor. "2M did not vary significantly 
between cell types. 
The ability of the analogues to activate TRPV1 was evaluated using fluorometric 
calcium flux assays (Figure 3.3). Previous studies have shown that ER calcium release 
was a precursor to GADD153 induction and epithelial lung cell death (19). TRPV1-OE 
cells treated with increasing concentrations of nonivamide and n-(3,4-
dihydroxybenzyl)nonanamide exhibited statistically significant increases in cytosolic 
calcium flux (15-20 fold) relative to untreated cells. The EC50 values were 1.5 µM and 
9.6 µM, respectively. All other nonivamide variants were essentially inactive even at 
concentrations ~150x the EC50 for nonivamide. Calcium flux dose-response curves for all 
analogues are shown in Figure 3.3. Calcium flux data at 2, 20 and 100 $M are also shown 
in Table 3.1.  
Molecular modeling techniques were used to model molecular interactions 




research has shown that capsaicin binds between transmembrane domains 3 and 4 to 
activate TRPV1, likely interacting with residues Y511, S512, L547, W549, and T550 (9-
14, 20). Capsaicinoid analogue structures were optimized as described in Methods. 
Representative figures for the docking analysis of nonivamide, n-benzylnonanamide n-(3-
hydroxy-4-methoxybenzyl)nonanamide  and n-(4-hydroxybenzyl)nonanamide  are shown 
in Figure 3.4, panels a-e.  
The dose-response cytotoxicity profile of each analogue was determined. 
Cytotoxicity (LC50) data for each cell type and analogue are presented in Table 3.2. 
TRPV1-OE cells were most sensitive to nonivamide and n-(3,4-
dihydroxybenzyl)nonanamide with LC50 values of 1 and 3.4 $M, respectively. All other 
analogues exhibited cytotoxicity at concentrations above 60-70 $M. BEAS-2B cells were 
also sensitive to nonivamide and n-(3,4-dihydroxybenzyl)nonanamide with LC50 values 
of 114 and 16.1 $M respectively, and were sensitive to most other analogues only at 
concentrations greater than the LC50 for nonivamide. NHBE cells were sensitive to most 
of the analogues at concentrations between 150 $M and 200 $M, with LC50 for 
nonivamide of 160 µM, consistent with a lower level of TRPV1 expression relative to 
TRPV1-OE and BEAS-2B cells. Results in Table 3.2 generally indicate that decreased 
TRPV1 activation correlated with decreased toxicity for all lung cell types tested, but also 
show that the toxicity of n-benzylnonanamide, n-(3-methoxybenzyl)nonanamide, and 3-
methoxy-4-(nonamidomethyl)phenyl sulfate are the result of non-TRPV1-mediated 
events since the LC50 values in all three cell types was similar. Finally, NHBE cells were 
less sensitive to n-(3,4-dihydroxybenzyl)nonanamide than BEAS-2B and TRPV1-OE 




Previous studies have show that activation of TRPV1 in BEAS-2B and TRPV1-
OE cells leads to ER stress, PERK pathway activation, and GADD153 expression (19). 
GADD153 mRNA expression was used as a quantifiable marker of ER stress activation 
by the capsaicinoid analogues. Results for GADD153 induction in TRPV1-OE cells 
treated at 2, 20 and 100 $M, and BEAS-2B and NHBE cells treated at 200 $M are shown 
in Table 3.3.  Significant GADD153 induction was observed in TRPV1-OE cells treated 
with 2 $M nonivamide for 4 hours. At 20 $M, statistically significant increases in 
GADD153 were observed with nonivamide and n-(3,4-dihydroxybenzyl)nonanamide), 
while at 100 $M, induction was observed with nonivamide, n-(3,4-
dihydroxybenzyl)nonanamide, n-(3,4-dimethoxybenzyl)nonanamide,  
n-(4-hydroxybenzyl)nonanamide and n-(3-hydroxy-4-methoxybenzyl)nonanamide, in 
agreement with results from cytotoxicity (Table 3.2) and calcium flux (Figure 3.3, Table 
3.1) endpoints.  BEAS-2B cells showed increased GADD153 mRNA after 4 hour 
treatments with 200 $M nonivamide, n-(3-methoxybenzyl)nonanamide, n-(3,4-
dihydroxybenzyl)nonanamide, n-(4-hydroxybenzyl)nonanamide  
n-(4-trifluoromethylbenzyl)nonanamide and 3-methoxy-4-(nonamidomethyl)phenyl 
sulfate, again correlating with the ability of these compounds to cause cell death.  NHBE 
cells treated for 4 hours at 200 $M had statistically significant GADD153 induction in 
cells treated with 200 $M nonivamide and n-(3,4-dihydroxybenzyl)nonanamide, but 
increases caused by the other analogues were not statistically significant, due to high 





Statistical analysis confirmed significant inverse correlations between loss of cell 
viability and GADD153 expression in all three cell types (Figure 3.5). For TRPV1-OE 
cells, correlation statistics were performed to compare cell viability at 2.5, 25 and 100 
$M with GADD153 induction at 2, 20 and 100 $M, respectively. Cell viability and 
GADD153 induction in TRPV1-OE cells after treatment with analogues at 100 $M was 
not statistically correlated, but it was at 2 and 20 $M. At 100 $M analogues likely 
mediate cell death through non-TRPV1-mediated and calcium-independent pathways that 
may or may not alter GADD153 expression levels. For BEAS-2B and NHBE cells, 
correlation statistics were used to compare cell viability after treatment for 24 hours with 
200 $M analogue and GADD153 induction after a 4 hour treatment of 200 $M analogue. 
In BEAS-2B and NHBE cells, cell viability results were inversely correlated to 
GADD153 induction.  
Correlation statistics were also performed to investigate the relationship between 
cell viability and calcium flux in TRPV1-OE cells (Figure 3.6). Calcium flux results at 2, 
20, and 100 $M were compared to cell viability at 2.5, 25, and 100 $M, respectively. In 
TRPV1-OE cells, calcium flux at 2 $M was not correlated to cell death, but statistically 
significant inverse correlation was found at 20 and 100 $M.  Correlation statistics were 
also performed to investigate the relationship between calcium flux and GADD153 
induction in TRPV1-OE cells with paired concentrations of 2 $M, 20 $M and 100 $M 
(Figure 3.7). For all three concentrations, calcium flux and GADD153 induction was 
significantly correlated.  
Alternate non-TRPV1-mediated mechanisms of toxicity were evaluated for n-




(3,4-dihydroxybenzyl)nonanamide was TRPV1 mediated, TRPV1-OE cells were co-
treated with n-(3,4-dihydroxybenzyl)nonanamide and the TRPV1 antagonist LJO-328 
(Figure 3.8). Unlike nonivamide, the toxicity of n-(3,4-dihydroxybenzyl)nonanamide was 
not attenuated by LJO-328 co-treatment. Based on the structure, it was hypothesized that 
n-(3,4-dihydroxybenzyl)nonanamide may redox cycle leading to reactive oxygen species 
formation and cell death. Co-treatment with n-(3,4-dihydroxybenzyl)nonanamide and n-
acetylcysteine (NAC) showed that NAC attenuated cell death after treatment of TRPV1-
OE with 10 $M n-(3,4-dihydroxybenzyl)nonanamide. NAC was not protective against 
cytotoxicity in BEAS-2B cells treated with 25 $M n-(3,4-dihydroxybenzyl)nonanamide.  
The less potent analogues were also evaluated as potential antagonists of 
nonivamide toxicity to test whether they compete for TRPV1 binding. Co-treatment of 
TRPV1-OE cells with nonivamide and increasing concentrations of n-benzylnonanamide 
demonstrated that n-benzylnonanamide attenuated cell death at concentrations between 




TRPV1 has rapidly emerged as a promising therapeutic target.  Better 
characterization of this receptor, and its associated functions in various cells and tissues, 
is key to understanding its role in physiology, pathology and disease. TRPV1 is 
expressed in many tissue and cell types, and it can be difficult to translate results from 
one model to another. We have designed and characterized a set of capsaicinoid 




specific outcomes that can be used to study TRPV1 function in the lung, and to 
extrapolate results across models.  
To examine the structure activity relationships of the capsaicin analogues with 
TRPV1, calcium flux, GADD153 induction and cytotoxicity were evaluated in three 
different epithelial lung cell lines. We used these parameters as indications of TRPV1 
activation because they each represent a step in a proposed mechanism of TRPV1-
mediated cell death for these lung cells. TRPV1-mediated calcium flux is commonly used 
to quantify TRPV1 activation, and causes ER stress (21). Previous work has shown that 
TRPV1 activation induces GADD153 expression as a marker of ER stress (19) and that 
this pro-apoptotic gene product was a prerequisite to cell death (22-24). By measuring 
calcium flux, GADD153 induction and cell death, three different consequences of 
TRPV1 activation were simultaneously evaluated to examine how they correlated and 
whether or not they represent an alternative pathway, leading to cell death for 
nonivamide, because these cells were not protected from cell death by TRPV1 
antagonists. 
Data indicate that capsaicinoid analogues with specific structural features caused 
significant calcium flux, GADD153 induction, and cell death in primary and 
immortalized human lung epithelial cells in a TRPV1-dependent manner. TRPV1-OE 
cells were highly susceptible to capsaicinoid analogues with both a 4-hydroxy moiety and 
an adjacent 3-position methoxy or hydroxy group (i.e., nonivamide and n-(3,4-
dihydroxybenzyl)nonanamide), with nonivamide being most potent and cytotoxic. The 
presence of only a 4-hydroxy group was not sufficient to activate TRPV1 and removing 




switching the 4-hydroxy and 3-methoxy moieties, ablated TRPV1 activation and 
cytotoxicity in TRPV1-OE cells, with similar results in BEAS-2B and NHBE cells.  
These results show that the 4-hydroxy and adjacent 3-methoxy moieties are requisite 
structural features for maximum TRPV1 activation, ER stress, and cell death in all three 
lung cell types regardless of their level of TRPV1 expression and indicate a correlation 
between TRPV1 activation and toxicity. These data agree with previous structure activity 
relationship analyses indicating that presence of a group at the 3-position, in addition to a 
4-position hydroxy, are essential for the formation of an optimum and productive ligand-
receptor complex (7).  
Quantitative real-time PCR results confirmed that TRPV1-OE cells expressed the 
most TRPV1 mRNA (Figure 3.2). These results were expected since TRPV1-OE cells 
were engineered to over-express TRPV1 under the control of a CMV promoter (18). The 
TRPV1-OE cells were most sensitive to select analogues and to other known TRPV1 
agonists indicating that TRPV1 expression is a primary determinant of toxicity in cells. A 
similar evaluation of mRNA comparisons was previously carried out in our laboratory 
using TRPV1-OE, BEAS-2B and A549 cells (18) showing similar relationships between 
TRPV1 mRNA abundance and LC50.  
Molecular modeling studies to investigate interactions between TRPV1 and 
capsaicin analogues also agreed with previous literature reports of predicted capsaicin-
TRPV1 ligand-receptor interactions. The structures of TRPV1 used for molecular 
modeling are often based off of a structurally similar voltage-dependent potassium (Kv) 
channel with 6 transmembrane domains since they were described as having similar 




capsaicin binding interaction induces a conformational change in the receptor, which 
opens the pore-loop and allows ions to flow through (10). It has also been proposed that 
transmembrane domains 3 and 4 form a paddle structure, similar to potassium ion 
channels, and the paddle shifts to permit capsaicin and vaniolloid agonist binding on the 
intracellular side of the channel (10, 11, 26). Mutation studies by Jordt and Julius (2002) 
indicate that human TRPV1 residue Y511 confers capsaicin sensitivity to the receptor, 
which was identified because chickens lack the corresponding residue and pain responses 
to capsaicin (12). Additional studies predict that capsaicin and other vanilloid agonists 
interact with TRPV1 transmembrane domains 3 and 4 at residues Y511, S512, L547, 
W549 and T550. (9-14, 20)  The vanilloid ring of capsaicin is hypothesized to have pi 
stacking interactions with W549, and the hydrophobic tail of the molecule likely interacts 
with Y511 forming a chemical tether between the two helices that causes a structural 
change, rendering the channel more susceptible to opening at a given temperature. 
Our results show that nonivamide likely interacts with TRPV1 similarly to 
capsaicin, at residues Y511 and W549 (Figure 3.4, panel a). The predicted binding 
interactions between TRPV1 and n-benzylnonanamide did not exhibit the same 
characteristics as nonivamide and its “nonproductive” interactions correlated with a lack 
of agonist activity. N-benzylnonanamide did appear to interact with TRPV1 to some 
extent, presumably by binding to the helices by associating with Y511 as indicated by its 
ability to attenuate the toxicity of nonivamide. Docking studies of n-(3-hydroxy-4-
methoxybenzyl)nonanamide also appeared to lack favorable interactions, with the 
vanilloid ring primarily interacting also with Y511. Docking of n-(4-




populated. The lowest energy cluster at -8.5 kcal/mole was associated with a 
conformation in which the analogue was aligned between transmembrane domains 3 and 
4 but did not form hydrogen bonds with W549 or Y511. The most highly populated 
cluster at -7.5 kcal/mole showed the analogue backed into the binding site, but did not 
form any predicted hydrogen bonds, in agreement with the results showing minimal 
potency for this analogue. 
Previous studies determined EC50 values for nonivamide in BEAS-2B, TRPV1-
OE, and NHBE cells, providing a positive control for TRPV1 activation in these 
experiments (15). In our model, nonivamide provides results identical to those seen with 
the prototypical TRPV1 agonist, capsaicin. Based on this, we expected to nonivamide to 
have high relative potency in comparison to the other analogues in terms of calcium flux, 
GADD153 induction and cytotoxicity. As expected, nonivamide induced significant 
calcium flux in TRPV1-OE cells, and significantly increased GADD153 expression in all 
three cell types indicative of ER stress. Nonivamide also caused significant cell death in a 
dose-dependent manner, which is consistent with prior studies. (15, 19)  
The benefit of working with TRPV1-OE cells is that TRPV1-mediated effects are 
magnified in these cells. This facilitated comparisons with the other cell types, 
characterizing the responses as meaningful and TRPV1-mediated. If results were 
inconsistent between TRPV1-OE and other cell types, we focused on TRPV1-
independent mechanisms. For example, if an analogue was highly toxic in BEAS-2B 
and/or NHBE cells, but was relatively nontoxic in TRPV1-OE cells, the toxicity of that 
analogue was not likely predominately TRPV1-mediated. To illustrate, the 3-methoxy-4-




permeable and would not cause significant TRPV1-mediated cell death. However, this 
compound was equally toxic in all three cell types, with similar LC50 values of about 60-
90 $M. Based on the similarities in cytotoxicity across cell types and inconsistent results 
in other markers (i.e., calcium flux, GADD153 induction) of TRPV1 activation, these 
results indicate 3-methoxy-4-(nonamidomethyl)phenyl sulfate toxicity was TRPV1-
independent. The results for n-(3-methoxybenzyl)nonanamide and n-(4-
hydroxybenzyl)nonanamide in Table 3.3 show a similar trend, suggesting they too are 
cytotoxic by alternative mechanisms. 
The capsaicinoid variant that produced significant cytotoxicity was n-(3,4-
dihydroxybenzyl)nonanamide. Similar to nonivamide,  
n-(3,4-dihydroxybenzyl)nonanamide induced significant calcium flux and, induced 
GADD153 in all three cell types when treated at concentrations above its LC50, and 
caused cell death. The relative EC50 values of n-(3,4-dihydroxybenzyl)nonanamide and 
nonivamide in calcium flux experiments was ~10 $M as compared to ~2 $M indicating 
that nonivamide was ~5x more potent in eliciting calcium flux.  In TRPV1-OE and 
NHBE cells, the LC50 for n-(3,4-dihydroxybenzyl)nonanamide was close to that for 
nonivamide itself. Interestingly, in BEAS-2B cells, n-(3,4-dihydroxybenzyl)nonanamide 
was ~6 times more toxic than nonivamide, indicating that  
n-(3,4-dihydroxybenzyl)nonanamide toxicity was not completely TRPV1-mediated. This 
conclusion was supported by results showing that the TRPV1 antagonist LJO-328 did not 
attenuate calcium flux or GADD153 induction (data not shown) or cell killing due to the 
n-(3,4-dihydroxybenzyl)nonanamide (Figure 3.8). We have yet to determine the specific 




CYP1A2 and 2C19) of capsaicin, is toxic to cells, but data showing an attenuation of 
toxicity by n-acetylcysteine (Figure 3.9) suggest it involves redox cycling and oxidative 
stress which may also contribute to GADD153 induction via the Nrf2/Keap1 pathway 
(27).  
Two analogues were essentially nonfunctional in these assays. N-
benzylnonanamide may function as a weak TRPV1 antagonist by virtue of its ability to 
potentially compete for Y511, but it did not activate TRPV1. N-(3,4-
dimethoxybenzyl)nonanamide may be a good negative control for future studies when 
receptor blockade is not desired, but the remaining analogues may be weak agonists of 
TRPV1 and may prove useful in structure related metabolism studies of nonivamide, 
capsaicin and related compounds and the relevance of metabolism to alter responses to 
related channels. 
 In conclusion, all cell types showed statistically significant inverse correlations 
between cell viability and GADD153 induction, confirming the hypothesis that TRPV1 
activation causes ER stress, leading to cell death. In all of the cell types used, there are 
additional cellular events that may modulate GADD153 expression and cell death, but the 
results herein confirm that GADD153 induction/ER stress after treatment with various 
capsaicinoid analogues is TRPV1-mediated. 
Collectively, a more thorough understanding of capsaicinoid-TRPV1 structure 
activity relationships was achieved and the results more clearly define how TRPV1 
functions in lung cells, how capsaicinoid variants and metabolites alter cellular function. 




mediated cell death in lung cells, which should help elucidate mechanisms of 
















Figure 3.2. Quantification of TRPV1 mRNA in different lung cell types. Copies of 
TRPV1 were normalized to copies of "2M, a housekeeping gene. Data are represented as 
average copies TRPV1/1,000 copies "2M with error bars indicating ± standard error of 
the mean. *, p<0.0001 compared to TRPV1-OE, #, p=0.044 compared to BEAS-2B, 





Figure 3.3. Calcium flux dose-response in TRPV1-OE cells after treatment with 
capsaicinoid analogues. Calcium flux was measured on a NOVOStar plate reader as 
described in Methods. Filled squares: nonivamide, open squares:  
n-(3,4-dihydroxybenzyl)nonanamide, filled circles:  
n-(3-hydroxy-4-methoxybenzyl)nonanamide, open triangles:  
3-methoxy-4-(nonamidomethyl)phenyl sulfate, filled triangles indicate  
n-benzylnonanamide, inverted filled triangles: n-(3-methoxybenzyl)nonanamide,  
filled diamonds: n-(3,4-dimethoxybenzyl)nonanamide, open inverted triangles: n-(4-
trifluoromethylbenzyl)nonanamide, and open diamonds:  
n-(4-hydroxybenzyl)nonanamide. * indicates lowest concentration of analogue causing 
statistically significant calcium flux, p<0.05 by one-way ANOVA. Data are represented 












Figure 3.4. Molecular modeling. Representative molecular modeling images of (a) 
nonivamide, (b) n-benzylnonanamide, (c) n-(3-hydroxy-4-methoxybenzyl)nonanamide, 
and for n-(4-hydroxybenzyl)nonanamide (d) lowest energy cluster (-8.5 kcal/mole) and 
(e) most highly populated cluster (-7.5 kcal/mole). Analogues were docked between 
transmembrane domains 3 and 4 of TRPV1. Potential hydrogen bonding interactions 
were determined by the software, and inter-atom distances are indicated with angstrom 





































Figure 3.5. Inverse correlation of cell viability and GADD153 induction. Cell viability 
was assayed after 24-hour treatment as described in Methods. GADD153 induction was 
measured using quantitative PCR after 4-hour treatment. TRPV1-OE cell viability after 
treatment with 2.5 µM, 25 µM, and 100 µM analogue was compared to GADD153 
induction after treatment with 2 µM, 20 µM, and 100 µM analogue respectively (panels a, 
b and c). (d) BEAS-2B cell viability after 200 $M analogue treatment compared to 
GADD153 induction after treatment with 200 $M analogue. (e) NHBE cell viability after 
200 $M analogue treatment compared to GADD153 induction after treatment with 200 
$M analogue. For all cell types, statistical analysis to determine significant inverse 




































































Figure 3.6. Inverse correlation of cell viability and calcium flux in TRPV1-OE cells. Cell 
viability was assayed after 24-hour treatment as described in Methods. Calcium flux was 
measured using a NOVOstar plate reader as described in Methods. TRPV1-OE cell 
viability after 2.5 $M, 25 $M, and 100 $M analogue treatment was compared to 
maximum calcium flux after 2 $M, 20 $M, and 100 $M analogue treatment, respectively 
(panels a, b and c).  Statistical analysis to determine significant inverse correlation is 







































Figure 3.7. Correlation of calcium flux and GADD153 induction in TRPV1-OE cells. 
Calcium flux was measured using a NOVOstar plate reader as described in Methods. 
GADD153 induction was measured using quantitative PCR after 4-hour treatment. 
TRPV1-OE maximum calcium flux and GADD153 induction were compared after 2 $M, 
20 $M and 100 $M analogue treatment (panels a, b and c). Statistical analysis to 
determine significant correlation is represented by the Pearson correlation value ‘r’ and is 










































Figure 3.8. Treatment of TRPV1-OE cells with LJO-328 and NAC to modulate n-(3,4-
dihydroxybenzyl)nonanamide induced toxicity. Cell viability was assayed after 24-hour 
treatment as described in Methods.  (a) TRPV1-OE cell viability dose-response after 
treatment with LJO-328 (open triangles), nonivamide (filled squares), n-(3,4-
dihydroxybenzyl)nonanamide (filled circles) alone, LJO-328 with nonivamide (open 
squares), LJO-328 with n-(3,4-dihydroxybenzyl)nonanamide (open circles). (b) TRPV1-
OE and BEAS-2B cells treated with n-(3,4-dihydroxybenzyl)nonanamide (10 and 25 µM, 
respectively), alone or in the presence of NAC (2.5 mM). * indicates statistically 
significantly different (p<0.05) from treatment with n-(3,4-dihydroxybenzyl)nonanamide 
alone, # indicates statistically significant (p<0.05) from treatment with NAC alone as 
determined using one-way ANOVA. Data are represented as mean cell viability % of 
















Figure 3.9. Evaluation of antagonist activity of n-benzylnonanamide. Comparison of cell 
viability at 1.5 $M nonivamide alone (0 $M n-benzylnonanamide), or cells treated with 
both compounds. One-way ANOVA was used to determine stastical significance between 
the groups with Dunnett’s multiple comparison test post-hoc testing. *p< 0.01 compared to 
nonivamide alone. Data are represented as average % cell viability as compared to 




Calcium Flux in TRPV1-OE Cells in Response to Various Capsaicinoid Agonists at 2, 20 and 100 !M. 
 
Calcium flux was assayed using a NOVOstar plate reader as described in Methods. Maximal baseline responses were 
subtracted from the maximal response after treatments were added. Data are shown as calcium flux for each of 3 






LC50 Values in Various Cell Types after Treatment with Capsaicinoid Analogues 
 




GADD153 Expression in Various Cell Types after Treatment with Capsaicinoid Analogues 
  
Cells were treated with capsaicinoid analogues for 4 hours (previously determined to be the peak induction after nonivamide 
treatment). TRPV1-OE cells were treated at 2 !M, 20 !M and 100 !M, and NHBE and BEAS-2B cells were treated at 200 
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CONTRIBUTIONS OF TRPV1, ENDOVANILLOIDS AND  
ENDOPLASMIC RETICULUM STRESS TO LUNG CELL  





 Endogenous agonists of the TRPV1 receptor (endovanilloids) have been 
implicated as mediators of lung inflammation and injury during experimental sepsis and 
other causes of systemic inflammation.  The current study tests the hypothesis that 
pulmonary inflammation and lung injury elicited by lipopolysaccharides (LPS; 
endotoxin) occur via the formation of pneumotoxic endovanilloids that activate TRPV1 
in the lung. In human lung cells, plasma membrane and endoplasmic reticulum (ER) 
populations of TRPV1 differentially regulate cytokine gene expression and cell death 
after TRPV1 activation.  Calcium efflux from the ER initiates the unfolded protein/ER 
stress response, leading to cell death via EIF2!K3 activation, G1/S arrest, and increased 
expression of proapoptotic growth arrest and DNA damage inducible gene 153 
(GADD153, CHOP or DDIT3). Treatment of human primary lung bronchial and 
bronchiolar epithelial, alveolar, and microvascular endothelial cells with nonivamide 
caused cytooxicity with LC50 values inversely proportional to TRPV1 expression, and 
induced GADD153 expression. Treatment of mice i.p. with LPS promoted systemic 
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inflammation and caused lung injury in mice in a TRPV1  and ER stress dependent 
manner. All responses to LPS were attenuated by cotreating mice with the TRPV1 
antagonist LJO-328 (5mg/kg, i.p) and in TRPV1-/- mice. These results provide 
compelling evidence that TRPV1 and pneumotoxic endovanilloids promote lung injury 
associated with systemic inflammation, and validate previous mechanistic findings on 
TRPV1 mediated lung cell toxicities in vitro. These results also highlight the possibility 
that modulation of TRPV1 may ameliorate lung injury due to systemic inflammation 
associated with sepsis or other causes. 
 
4.2 Introduction 
Lung injury and its most severe manifestation, acute respiratory distress syndrome 
(ARDS), cause severe morbidity and mortality.  Lung injury is defined as pulmonary 
edema and cellular damage resulting from loss of alveolar and vascular endothelial cell 
function and/or viability (1-4). Damage to the alveolar-capillary unit increases the flux of 
plasma fluid and protein into the alveolar spaces and inhibits O2/CO2 exchange (3-5). 
Studies have clearly shown that stimulation of the host immune system during 
sepsis/systemic endotoxemia causes lung injury, but the precise molecular mechanisms 
coupling infection and/or inflammation with lung injury remain poorly defined (1, 3, 4).   
It has been shown that endotoxemia and other common causes of lung injury 
induce the synthesis of a variety of small molecule immune system modulators including 
hydrogen sulfide (H2S), anandamide, leukotrienes (LTs), hydroxy- and 
hydroperoxyeicosatetraenoic acids (HETEs and HPETEs), and prostaglandins (6-12). 
These substances contribute to lung injury and the deleterious sequelae associated with 
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sepsis and burn injury (7, 10-12). Several of these substances are potent agonists of the 
TRPV1 (transient receptor potential vanilloid 1) receptor (7, 9, 12-14). 
TRPV1 is a transmembrane ligand gated calcium channel activated by capsaicin, 
the compound found in chili peppers that elicits a burning sensation. TRPV1 is also 
activated by temperatures >43oC, pH <6.2 (at 37oC) and a variety of exogenous and 
endogenous compounds (15-19). Known endogenous TRPV1 agonists (endovanilloids) 
include anandamide, leukotriene B4, 12(S)-HPETE and similar eicosanoids, and H2S.  
TRPV1 is expressed by tachykinin rich sensory neurons and various non-neuronal 
cells of the lung. Activation of TRPV1 in C- and A"-fibers in the lung causes pulmonary 
neurogenic inflammation, largely via the release of substance P and neurokinin A, two 
substances known to promote vascular leakage and edema (7, 14, 20-26). TRPV1 is also 
expressed by non-neuronal cells. In these cells TRPV1 is expressed on the plasma 
membrane and on the endoplasmic reticulum (ER) (27-30). Activation of TRPV1 on the 
plasma membrane of lung cells causes calcium influx and has been linked to increased 
immunomodulatory cytokine transcription and secretion. TRPV1-mediated increases in 
IL-6 and IL-8 likely promote pulmonary inflammation, neutrophilia and injury associated 
with capsaicin inhalation in rats (31). Conversely, activation of ER TRPV1 causes ER 
calcium depletion, ER stress, and cell death, which likely contributes to the extensive 
damage to epithelial cells throughout the airways and lungs of rats exposed to capsaicin 
aerosols (32). The neuronal release of tachykinins and the release of cytokines from 
epithelial cells, coupled with ER stress associated cell cycle arrest and cell death, 
presumably cause lung inflammation and injury by TRPV1 agonists. 
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There are several reports that multiple endovanilloids are produced during 
experimental sepsis and that ER stress is observed in damaged lungs of LPS-treated mice 
(7, 8, 10, 12, 14, 31-37). However, the possibility that TRPV1 and endovanilloids were 
responsible for the initiation of ER stress in lung cells was not investigated.  The 
hypothesis for this work is that lung injury resulting from systemic exposure to LPS is 
mediated, in part, by endovanilloids and TRPV1. This research utilizes a multi-faceted 
strategy including the assessment of TRPV1 activation, GADD153 expression (a marker 
for ER stress), and cell death in cultured primary human lung cells known to be targeted 
during sepsis, and an assessment of the contribution of TRPV1 and endovanilloids in 




Nonivamide (n-vanillylnonanamide), LPS (0110:B4), and anandamide (n-
arachadonoylethanolamine) were purchased from Sigma-Aldrich (St. Louis, MO). AM-
251 was purchased from Cayman Chemicals (Ann Arbor, MI).   Nonivamide and 
capsaicin have indistinguishable toxicity profiles in the human lung cells used in this 
study, but nonivamide is available in higher purity so it is used in experiments as the 
prototypical TRPV1 agonist. LJO-328 was provided by Dr. Jeewoo Lee (Seoul National 
University, Seoul, Korea).  PCR primers for mouse and human GADD153 and #-actin 
were synthesized by Integrated DNA Technologies (Coralville, IA). PCR primers for 
TRPV1 and #2M were synthesized by the University of Utah Core Facilities (Salt Lake 




4.3.2 Cell Culture 
Immortalized human bronchial epithelial cells (BEAS-2B) were purchased from 
American Type Culture Collection (Manassas, VA), and TRPV1 overexpressing BEAS-
2B (TRPV1-OE) cells were generated as described previously (31).  BEAS-2B and 
TRPV1-OE cells were cultured in LHC-9 media (BioSource International, Camarillo, 
CA). Primary human lung microvascular endothelial (HMVEC-L), small airway 
epithelial cells (SAEC) and normal human bronchial epithelial (NHBE) cells were 
purchased from Lonza (Walkersville, MD).  HMVEC-L cells were cultured in 
supplemented EGM-MV media, SAEC cells were cultured in SAGM media, and NHBE 
cells were cultured in BEGM media (Lonza, Walkersville, MD). Culture flasks for 
SAEC, NHBE, BEAS-2B and TRPV1-OE cells were coated with LHC basal media 
fortified with 30 µg/mL collagen, 10 µg/mL fibronectin, and 10 µg/mL bovine serum 
albumin.  Cells were maintained between 30 and 90% maximum density. 
4.3.3 Cytotoxicity/Dose Response Assays 
Cells were subcultured into 96 well plates and grown to ~90% confluence.  Cells 
were treated for 24 hours at 37ºC with increasing concentrations of chemical.  Treatment 
solutions were prepared in LHC-9 media for BEAS-2B and TRPV1-OE cells and in 
OptiMEM I reduced serum media (Invitrogen, Carlsbad, CA) for NHBE, HMVEC-L and 
SAEC cells. Cell viability was quantified using the Dojindo cell counting kit-8 (Dojindo 






4.3.4 Semiquantitative Reverse Transcriptase PCR Analysis of 
GADD153 Gene Expression 
Cells were subcultured into 6 well cell culture plates and grown to ~90% density.  
HMVEC-L and NHBE cells were treated with nonivamide for varying durations at 37ºC.  
Total RNA was extracted from cells using the Invitrogen PureLink Micro-to-Midi Total 
RNA Purification System (Invitrogen, Carlsbad, CA), and 2.5 µg of the total RNA was 
transcribed into cDNA using Superscript III (Invitrogen, Carlsbad, CA).  cDNA 
corresponding to GADD153 and # -actin was amplified by PCR using 1 µL of the cDNA 
synthesis reaction, gene specific primers and GoTaq Green PCR Master Mix (Promega, 
Madison, WI). The PCR program used to examine the expression of both human and 
mouse GADD153 consisted of an initial 2 minute incubation at 94ºC, followed by 28 
cycles of 94ºC for 30 seconds, 54ºC for 30 seconds, and72ºC for 1 minute.  The program 
ended with 10 minutes at 72ºC.  PCR products were resolved on 1% SB buffer agarose 
gels.  Images were captured using a Gel-Doc imaging system (Bio-Rad, Hercules, CA).  
Product quantification was achieved by determining band intensities for each PCR 
product relative to #-actin, the internal PCR control, using the Gel-Doc density analysis 
tools in the Quantity One software program (Bio-Rad). Primers for human GADD153 
were: sense, 5'- GACCTGCAAGAGGTCCTGTC-3’; antisense,  
5’-TCGCCTCTACTTCCCTGGTC-3’; the PCR product was 395 nucleotides. Primer 
sequences for human #-actin were: sense, 5’-GACAACGGCTCCGGCATGTGGCA-3’; 
antisense, 5’-TGAGGATGCCTCTCTTGCTCTG-3’; the PCR product is 183 




4.3.5 Quantitative Real-Time PCR Analysis of TRPV1 
and GADD153 Expression in Human Cells 
Total RNA was isolated using the Invitrogen PureLink Micro-to-Midi Total RNA 
Purification System (Invitrogen, Carlsbad, CA). cDNA was prepared by using 1 µg of the 
total RNA transcribed into cDNA using Superscript III (Invitrogen, Carlsbad, CA). Real 
time PCR was performed using 1 µL cDNA diluted 1:100 and RT2 SYBR Green qPCR 
Master Mix from SABiosciences (Frederick, MD) on a Chromo 4 Real Time Detection 
System (Bio-Rad, Hercules, CA) using MJ Opticon Monitor 3 software. The PCR 
program used consisted of an initial 10 minute incubation at 95ºC, followed by 40 cycles 
of 95ºC for 15 seconds, 55ºC for 30 seconds, then 72ºC for 30 seconds. Experiments were 
performed in triplicate with a copy number standard curve for both the housekeeping 
gene (beta-2 macroglobulin, #2M) and the genes of interest (TRPV1 and GADD153). 
cDNA was diluted 1:100 for all samples.  Primer sequences for human #2M were: sense, 
5’ –GATGAGTATGCCTGCCGTGTG – 3’;  
antisense, 5’ –CAATCCAAATGCGGCATCT – 3’. Primer sequences for human TRPV1 
were: sense, 5’- CTGCGGACCCACTCCAAAA-3’;  
antisense, 5’-CCTCGTGAGGGCAATCCAC-3’.  
Primer sequences for human GADD153 were:  
sense, 5’-AGAACCAGGAAACGGAAACAGA-3’; a 
antisense, 5’-TCTCCTTCATGCGCTGCTTT-3’.  
4.3.6 Animals 
Experiments were performed on 20-25 g male CF1, C57BL/6 mice, and TRPV1 -
/- null C57BL/6 mice.  Mice were maintained in the University of Utah vivarium and 
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Institutional Animal Care and Use Committee (IACUC) authorization was obtained for 
all procedures and experimental protocols.   
4.3.7 LPS Induced Lung Injury 
Intraperitoneal injection of LPS was used as the immune system stimulant.  LPS 
(E.coli 0111:B4) was prepared in 0.9% saline, or in 98.4% saline, 1% ethanol, 0.5% 
Tween 20, and 0.1% DMSO for experiments where LJO-328 co-treatment was used.  
Mice were injected intraperitoneally (i.p.) with vehicle alone, 10 mg/kg or 15 mg/kg LPS, 
LPS 10 or 15 mg/kg with 5 mg/kg LJO-328, or 5 mg/kg LJO-328.  Animals were treated 
for 12 hours during which lung injury developed.  Animals were terminally anesthetized 
by i.p. injection of pentobarbital (100 mg/kg in 50% DMSO), and exsanguinated via 
cardiac puncture. Bronchial alveolar lavage (BAL) was performed using 0.4 mL saline, 
and the lungs were collected for gene expression analysis. Lung injury was also assessed 
histologically and by assaying changes in BAL protein content and lung water weight, as 
described below. 
4.3.8 Quantification of Lactate Dehydrogenase (LDH)  
in BAL Fluid 
Contents of the lung airspace were collected by lavage.  The trachea was 
cannulated using a blunt ended 22 gauge needle attached to a 1 mL syringe.  The lungs 
were gently infused with 0.4 mL of sterile saline and the fluid was recovered by gently 
pulling back on the syringe, repeated twice.  The fluid was clarified by centrifugation at 
1000 x g for 2 minutes at 4° C and the supernatant was assayed for soluble LDH activity 
and total protein content. LDH activity was quantified using the TOX-7 assay kit (Sigma-
Aldrich, St. Louis, MO).  Total protein was quantified using the Bicinchoninic Acid 
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(BCA) Assay Kit (Pierce, Rockford, IL).  Data for LDH activity are expressed as 
units/total mg of protein in the BAL fluid.  
4.3.9 Quantification of GADD153 Expression in Mouse Lung 
Lungs were removed and trimmed to remove the heart, trachea, bronchi, and 
connective tissues.  Lungs were placed in RNALater RNA Stabilization Reagent (Qiagen, 
Valencia, CA) at 4ºC for 24 hours and stored at -20ºC until analysis.  Tissues were 
homogenized and total RNA was isolated using the Invitrogen PureLink Micro-to-Midi 
Total RNA Purification System (Invitrogen, Carlsbad, CA). 2.5 µg of the total RNA was 
transcribed into cDNA using Superscript III (Invitrogen, Carlsbad, CA).  cDNA 
corresponding to GADD153 and # -actin was amplified by PCR using 1 µL of the cDNA 
synthesis reaction, gene specific primers and GoTaq Green PCR Master Mix (Promega, 
Madison, WI). The PCR program used to examine the expression of mouse GADD153 
was identical to the program used to quantify GADD153 mRNA in primary human cells. 
Primer sequences used for mouse GADD153 were: sense, 5’- 
GCAGCCATGGCAGCTGAGTCCCTGCCTTCC -3’;  
antisense, 5’- CAGACTCGAGGTGATGCCCACTGTTCATGC -3’. Primer sequences 
used for mouse #-actin are: sense, 5’- GTGACGAGGCCCAGAGCAAGAG -3’; 
antisense, 5’- AGGGGCCGGACTCATCGTACTC -3’. 
4.3.9 Quantification of Excess Lung Water Weight 
Net changes in lung tissue mass were determined. Mice were sacrificed and lungs 
were collected during necropsy.  The left lobe from each animal was weighed and heated 
for 48 hours at 55°C.  The lungs were weighed again and the change in mass was used to 
  
122 
quantify fluid accumulation and cellular infiltration in the lung as a consequence of LPS 
treatment.  Data are expressed as the change in lung wet weight to dry weight.  
4.3.10 Statistical Analysis 
Statistical analysis was performed using 95% confidence intervals as the limit for 
significance.  All results, excluding lung histopathology, are represented as mean ± 
standard deviation or mean with the 95% confidence interval (C.I.).  Post-hoc testing was 





 Cellular sensitivity to TRPV1 agonists depends on the relative amount of TRPV1 
expression, which varies by cell type and anatomical location. TRPV1 mRNA expression 
was quantified in TRPV1 overexpressing BEAS-2B cells (TRPV1-OE), BEAS-2B, 
A549, NHBE, SAEC, and HMVEC-L cell types using quantitative real time PCR 
techniques. TRPV1 expression was inversely correlated with LC50 values for the TRPV1 
agonist nonivamide (Figure 4.2).  
Primary human lung cells, chosen to mimic cells of the lung known to be targeted 
for damage during acute lung injury/ARDS (i.e., microvascular endothelial and alveolar 
type II cells), were treated with nonivamide to establish a dose response curve and 
determine the cytotoxic potential of capsaicin in these cells.  Primary human HMVEC-L, 
SAEC and NHBE cells were sensitive to nonivamide with LC50s of 150 $M, 160 $M and 
160 $M, respectively (Figure 4.3 panel A). Cell death due to nonivamide treatment was 
partially attenuated with LJO-328 cotreatment in HMVEC-L cells (data not shown). 
Preliminary data indicate that GADD153 mRNA is induced in NHBE and HMVEC-L 
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cells in a time-dependent manner after treatment with nonivamide at LC50 concentrations 
(Figure 4.3 panel B). 
 The role of TRPV1 in lung injury in vivo was investigated using a mouse model 
of septic/inflammatory lung injury.  LPS endotoxin was injected intraperitoneally into 
mice.  A hallmark of lung injury is the accumulation of inflammatory cells and fluid in 
the lung.  To determine the extent to which LPS treatment induced inflammation and 
edema in the lung, lungs were weighed and dried to quantify excess water weight and 
residual cellular material.  Mice treated with LPS exhibited a significant increase in water 
weight, approximately 12 mg H2O, relative to controls.  Increases in water weight were 
attenuated ~50% by LJO-328 co-treatment (Figure 4.4).  
Lung cell damage after LPS treatment was also quantified using an assay to 
determine soluble LDH activity in BAL fluid. Comparison of wild type LPS-treated 
mice, wild type mice co-treated with LPS (10 mg/kg) and the TRPV1 antagonist LJO-328 
(5 mg/kg) for 12 hours demonstrated significant attenuation of LPS-induced increases in 
BAL LDH by LJO-328  (Figure 4.5, panel A). Comparison between wild type and 
TRPV1 -/- mice treated with LPS (15 mg/kg) for 12 hours demonstrated that TRPV1-/- 
mice had significantly lower BAL LDH activity compared to wild-type mice, in 
agreement with the prior results using LJO-328 (Figure 4.5, panel B).   
GADD153 mRNA expression was also quantified as an indicator of TRPV1 
activation and ER stress induction in damaged lungs of LPS treated animals. GADD153 
mRNA levels were significantly induced in LPS treated mice compared to vehicle treated 
mice. In animals co-treated with LPS and LJO-328, GADD153 expression was reduced 
to near control levels, as it was in TRPV1 -/- mice (Figure 4.6, panels A and B).   
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Histopathological assessment of lung injury was performed on lung slices to 
gauge the severity of lung injury. Representative images are presented in Figure 4.7. 
Lungs of vehicle treated mice showed mild inflammation, occasional macrophages, and 
minimal bronchial or alveolar exudates. Lungs of LPS treated mice exhibited occasional 
emphysematous alveoli, increased numbers of macrophages, some neutrophils, and 
occasional alveoli containing eosinophilic proteinacious exudates. Lungs of LPS treated 
TRPV1-/- mice showed only mild inflammatory infiltrates with some eosinophilic 
material, similar to controls. Similar results were observed in LJO-328 cotreated mice 
(data not shown). 
Capsaicin is the prototypical TRPV1 agonist, but endogenous TRPV1 agonists 
also have the ability to activate TRPV1.  The endovanilloid anandamide was evaluated as 
a mediator of TRPV1 dependent lung injury using lung cells. HMVEC-L, SAEC, and 
NHBE cells were sensitive to anandamide with LC50 values of approximately 14 $M, 20 
$M, and 31 $M, respectively (Figure 4.8, panel A). TRPV1-OE and BEAS-2B cells 
exhibited LC50 values of ~22 $M and ~18 $M, respectively. For both TRPV1-OE and 
BEAS-2B cells, anandamide induced cytotoxicity was not significantly blocked by LJO-
328 or AM-251 co-treatment. (Figure 4.8, panels B and C)  Similar results were produced 
when GADD153 induction was examined after treatment with anandamide alone or in the 
presence of LJO-328 or AM-251. (Figure 8, panel D) These results indicate anandamide 
is likely toxic to human lung cells via non TRPV1 dependent mechanisms and that other 









 As research has progressed on the etiology of inflammation induced lung injury, a 
role for TRPV1 and endogenous agonists as potential mediators of injury has emerged. 
Although the exact mechanisms of cell death and damage in lung injury are not fully 
understood, continued investigation of this process is vital to the development of better 
models, new therapies, and ultimately the survival of thousands of patients each year.  
 To better characterize TRPV1 and associated functions in the lung, TRPV1 
expression and responses of primary human lung cells to the prototypical agonist 
nonivamide were studied. Microvascular, alveolar, and even bronchial epithelial cells are 
among cells targeted for damage during systemic inflammation arising from conditions 
such as sepsis and trauma. Treatment of SAEC, HMVEC-L, and NHBE cells with 
nonivamide produced cytotoxicity (Figure 4.3 panel A). SAEC, HMVEC-L and the 
primary BEAS-2B cognate NHBE cells were roughly equally sensitive to nonivamide 
(LC50 ~150 µM), consistent with their relative levels of TRPV1 expression (Figure 4.2). 
Preliminary data indicate that nonivamide induces GADD153 in HMVEC-L and NHBE 
cells in a time dependent manner (Figure 4.3 panel B).  
Injury of cells in the intact lung during sepsis/systemic endotoxemia is indeed 
much more complex than the simple in vitro cell culture studies described above. 
However, we postulated that the results observed in vitro would be reflected in the intact 
lung if pneumotoxic endovanilloids contributed to lung injury.  Preliminary data from our 
lab have indicated that intratracheal administration of capsaicin to mice induces 
GADD153 in the whole lung at least 2 fold as compared to PBS treated animals (data not 
shown). Experiments using the LPS model of lung injury confirmed that TRPV1 played a 
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role in lung injury due to LPS treatment.  Both TRPV1 antagonism using LJO-328 and 
TRPV1 knockout decreased inflammation and edema as evidenced by histological 
assessment of lung morphology, and by statistically lower LDH and lung water weight in 
LPS treated mice.  Histopathological results also provided some indication of alveolar-
capillary damage/edema and inflammatory cell recruitment in the lungs of LPS treated 
mice. It is anticipated that future immunohistochemical analysis of these lung slices for 
diagnostic markers of lung injury and ER stress will further confirm these results.  
Additionally, evaluation of inflammatory cytokine induction in BAL and optimization of 
time points and treatment doses should provide additional compelling results and support 
for our hypothesis on TRPV1 and endovanilloids as mediators of lung injury. A 
limitation of our results is that previous use and characterization of the LPS-model of 
induced sepsis has shown reproducible results, but that C57BL/6 mice experience a 
relatively mild inflammatory and lung injury response in comparison to other strains of 
mice and animal species (2).  We have observed differences in susceptibility between the 
CF1 and C57BL/6 mouse strains, which is reflected in the doses used and results 
presented herein.  
Responses to the prototype TRPV1 agonist capsaicin and the endovanilloid 
anandamide were compared to gain insight into whether endogenous TRPV1 agonists 
could cause lung injury through TRPV1 activation in lung cells. The results showing 
similar LC50 values for anandamide in all cell types independent of TRPV1 expression, as 
well as the inability of TRPV1 and CB1/2 antagonists to block anandamide toxicity in 
TRPV1-OE and BEAS-2B cells indicated that anandamide toxicity was not completely 
TRPV1 mediated. Since the in vitro data indicate anandamide is likely toxic via non 
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TRPV1 dependent mechanisms, anandamide is not likely the endovanilloid responsible 
for the observed TRPV1 mediated responses in vivo.  
Collectively, these results provide novel insights into the role of TRPV1 and 
endogenous TRPV1 agonists as mediators of lung injury in the context LPS induced 
inflammation.  These studies couple in vitro mechanistic results showing that TRPV1 
agonists cause lung cell death through ER stress with results that LPS induced lung injury 
and GADD153 expression in vivo are a consequence of TRPV1 activation by endogenous 
agonists such as anandamide, but indicates that endovanilloids other than anandamide 
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Figure 4.2. Quantitative real-time PCR copies of TRPV1 fold #2M control in a variety of 
cell types compared to their approximate nonivamide LC50 concentrations. Cytotoxicity 
assays and real-time PCR were carried out as described in Methods. Average copies 
TRPV1 and LC50 values in these cells were significantly inversely correlated with a 






Figure 4.3.  Dose-response cytotoxicity for nonivamide in NHBE, SAEC and HMVEC-L 
cells and nonivamide-induced GADD153 expression in NHBE and HMVEC-L cells. 
Panel A. NHBE, SAEC and HMVEC-L cells were sensitive to nonivamide at 
concentrations above 150 $M. NHBE cells are represented with open circles, SAEC cells 
are represented by open triangles and HMVEC-L cells are represented with closed 
squares.  Data are shown as % viability of untreated control cells. Panel B. Preliminary 
Data. Semi-quantitative GADD153 mRNA expression was examined in NHBE and 
HMVEC-L cells treated with approximate LC50 concentrations of nonivamide (160 and 
175 $M, respectively) at varying time points. Data are presented as fold control relative 














Figure 4.4. Changes in mouse lung water weight. The change in weight indicates edema 
and cellular accumulation in lungs of CF1 mice treated with vehicle (white bars, n=6), 
LPS (10 mg/kg) (light grey bars, n=6), LPS (10 mg/kg) and LJO-328 (5 mg/kg) (dark 
grey bars, n=6) and LJO-328 (5 mg/kg) (black bars, n=6) alone. Statistical differences 
(p<0.05) between the vehicle, LPS-treated, LPS+LJO-328, and LJO-328 treated groups 
were observed (*). # indicates statistical differences between LPS treated and LPS + 
LJO-328 treated groups. Statistical analyses were performed by one-way ANOVA and 







Figure 4.5. Panel A. LDH activity in BAL from CF1 mice. LDH activity is shown for 
vehicle treated CF1 mice (white bars, n=6), LPS (10 mg/kg) treated mice (light grey bars, 
n=6), mice co-treated with both LPS (10 mg/kg) and LJO-328 (5 mg/kg) (dark grey bars, 
n=6), and mice treated with LJO-328 alone (black bars, n=6) was examined. LPS treated 
wild-type mice had statistically significant increases (*) in BAL LDH. Panel B. Soluble 
LDH activity in BAL from LPS-treated C57BL/6 mice was evaluated in vehicle treated 
mice (white bars, n=5), LPS treated wild-type mice (light grey bars, n=5) and LPS treated 
TRPV1-/- mice (dark grey bars, n=3).  Statistically significant differences (#) were 
observed between LPS treated wild-type mice and LPS treated TRPV1 -/- mice at the 
95% C.I. using one-way ANOVA analysis and Newman-Keuls post-test. * indicates 






















Panel A.  
 
Figure 4.6. Expression of GADD153 mRNA in mouse lungs. Treatment groups are 
described in each panel and data are expressed as fold control relative to #-actin loading 
control. Panel A.  LPS resulted in a statistically significant increase in GADD153 mRNA 
induction relative to vehicle treatment, p <0.05 using one-way ANOVA and Dunnett’s 
multiple comparison test, n=6 for each group. Panel B. Statistically significant decreases 
(*) in the GADD153 PCR products were seen in LPS treated TRPV1-/- mice compared to 
wild-type C57BL/6 mice using one-way ANOVA and Newman-Keuls post-testing, p< 
0.05. For vehicle and LPS treatment groups, n=5. For TRPV1-/- , n=3. # indicates 




















Figure 4.7. Mouse lung histology.  Lungs were fixed in situ by infusing with 10% 
neutral-buffered formalin, removed, and placed in fixative solution.  5 µm sections were 
prepared, stained with eosin and hematoxylin, and analyzed.  Representative mouse lung 
sections are shown for vehicle treated wild-type C57BL/6 mice, wild-type mice treated 








Figure 4.8. Anandamide dose response and GADD153 induction in several lung cell 
types. Panel A. Anandamide dose response curves for NHBE, SAEC and HMVEC-L 
cells. NHBE, SAEC and HMVEC-L cells were sensitive to anandamide at concentrations 
above 10 $M. NHBE cells are represented with open circles, SAEC cells are represented 
by open triangles and HMVEC-L cells are represented with closed squares.   Data are 
shown as % viability of untreated control cells. TRPV1-OE (panel B) and BEAS-2B 
(panel C) cells were treated with anandamide alone or in the presence of LJO-328 
(TRPV1 antagonist) or AM-251 (CB1/2 receptor antagonist) for 24 hours as described in 
Methods. None of the groups were significantly different from each other as determined 
using one-way ANOVA: for TRPV1-OE cells, p=0.44 and for BEAS-2B cells p=0.73. 
Panel D. TRPV1-OE and BEAS-2B cells were treated treated with anandamide (AEA) 
alone (25 $M) indicated by closed squares; or in the presence of LJO-328 (20 $M 
TRPV1-OE or 50 $M BEAS-2B) indicated by open triangles, or AM-251 (2.5 $M both 
cell types) indicated by open circles. * denotes value significantly elevated over untreated 
control, and % denotes a value significantly elevated over anandamide alone, using one-






Figure 4.8 A. 
 




Figure 4.8 C.  
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Everyday experiences are enriched by sensations of touch, taste, sight, smell and 
sound. The ability to differentiate between beneficial and dangerous experiences is 
important to be able to minimize harm as discussed in Chapter 1. TRP receptors are 
critical sensors of harmful environmental conditions, and TRPV1 is no exception. 
TRPV1 receptors do not function like light switches with simple on/off functionality; 
rather they are sensitive to changes in nearby conditions including intracellular TRPV1 
distribution, cellular pH, extracellular ion concentrations, and posttranslational 
modification including phosphorylation state, nitrosylation, and glycosylation (1-5). As 
previously discussed, TRPV1 receptors are activated by many chemical irritants, 
exogenous substances, and endogenous inflammatory mediators. Varied activation states 
and numerous agonists make TRPV1 characterization difficult; nevertheless this receptor 
presents a challenge to scientists to elucidate the functional traits of TRPV1. Although it 
is the topic of much research, TRPV1 characterization is limited and many features of 
this receptor are not yet completely understood. 
The goal for this work was to better understand how TRPV1 agonists cause 
damage to the lung epithelium through characterization of: 1) the mechanism of TRPV1 
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mediated cell death, 2) structure activity relationships of capsaicin analogues in different 
lung cell types, and 3) the role of TRPV1 in lung injury resulting from severe systemic 
inflammation, which increases select endovanilloids. We sought to answer the following 
questions with this research: why do TRPV1 agonists kill human lung epithelial cells? 
Which structural features of capsaicin and nonivamide are key for TRPV1 activation, and 
what are the consequences? Can we use chemical variants of nonivamide to better 
understand TRPV1 activation in in vitro models exhibiting different responses? Does 
TRPV1 play a role in lung injury after systemic inflammatory events, such as sepsis or 
trauma, where endovanilloids are known to be upregulated? We were able to answer each 
of these questions, although for each question answered many additional questions 
presented themselves. Indepth conclusions were presented at the end of each chapter. 
This chapter presents an integrated summary of the three main chapters, suggestions for 
additional experiments, and a proposed mechanism of TRPV1 activation in human lung 
epithelial cells (Figure 5.1). 
 
 
5.1 Chapter 2 
 
Chapter 2 described the results of our investigation into the mechanism of TRPV1 
mediated lung cell death. In several different cell types it was determined that TRPV1 
activation leads to calcium release from the ER, causing ER stress and cell death. TRPV1 
agonist treatment caused ER stress responses in a manner consistent with known ER 
stress-inducing agents, and induced cytotoxicity through the PERK pathway. TRPV1 
agonists did not induce ER stress with LJO-328 (TRPV1 antagonist) cotreatment, or in 
cells that do not express functional TRPV1 (6). Future studies for this portion of the 
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project include determining the ability of other TRPV1 agonists and antagonists to induce 
or prevent ER stress. Studies to determine whether or not ER stress is induced after 
neuronal TRPV1 activation and to what extent sensory neuron activation contributes to 
ER stress in nonneuronal cells would shed light on the cell/tissue specificity and 
fundamentals of this response in the lung. Consider also that TRPV1 activation may 
possibly induce ER stress through other pathways.  In addition to EIF2!K3, other 
proximal sensors of ER stress are ATF6 and IRE1 (7). Downstream effects of these other 
pathways may be compensatory and, depending on the circumstances, may enhance or 
attenuate the deleterious effects of TRPV1 in different lung cells and in the intact lung. 
TRPV1 induced ER stress is presumably mediated by the intracellular pool of TRPV1 in 
nonneuronal cells, and shifting the majority of TRPV1 to the cell surface by unknown 
conditions similar to what occurs with LJO-328 pretreatment of TRPV1-OE cells may 
change the magnitude of ER stress induction or abrogate the response (8). Additionally, 
GADD153 is pro-apoptotic, but cell death due to capsaicin is generally oncotic. It would 
be interesting to evaluate the temporal relationship between ER stress and markers of 
apoptosis, necrosis, and/or autophagy to determine the exact mechanisms of cell death.  
 
 
5.2 Chapter 3 
 
Chapter 3 identified requisite structural features of nonivamide for TRPV1 
activation through the examination of structure activity relationships for capsaicin 
analogues and TRPV1. Calcium flux, ER stress/GADD153 induction, and cell death were 
used to quantify TRPV1 activation. Modifying the core structure of nonivamide altered 
the ability of the analogues to interact with TRPV1, and molecular modeling confirmed 
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the essential structural features for TRPV1 activation, ER stress and cell death as 
previously identified in the literature (9-17). Future experiments to expand on these 
results include measurement of TRPV1 protein expression for confirmation of TRPV1 
mRNA quantification. Metabolism studies of analogues may identify metabolites with 
the ability to activate TRPV1, since cytochrome P450 enzymes metabolize capsaicin 
(18). Investigation of n-(3,4-dihydroxybenzyl)nonanamide and whether it is inducing ER 
stress through alternate pathways (e.g., Nrf2/Keap1) instead of TRPV1 would enhance 
our understanding of its toxicity and would help extrapolate responses observed in vitro 
to responses of cells in the intact lung. Additional molecular modeling of analogues with 
variations in other portions of the nonivamide structure would also improve knowledge of 
the TRPV1 vanilloid binding site. Refinement of modeling parameters would strengthen 
the validity of these results – for example, a larger portion of TRPV1 could be modeled 
in a lipid environment to reproduce more physiologically relevant interactions.  
 
 
5.3 Chapter 4 
 
Chapter 4 described a potential role of TRPV1 as a mediator of endovanilloid-
related lung injury. Endovanilloids have been implicated in lung inflammation and injury 
during experimental sepsis and following burn injury (19-35). This study tested the 
hypothesis that LPS-induced systemic inflammation could cause lung injury via the 
formation of pneumotoxic endovanilloids that migrate via systemic circulation and 
activate TRPV1 in the lung. TRPV1 activity was examined in primary human lung cells 
and in mice with and without TRPV1 antagonist cotreatment, and without TRPV1 
expression (TRPV1-/-).  These studies showed that TRPV1 genetic knockout or receptor 
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inhibition conferred protection from LPS-induced lung injury. Protective effects are 
presumably due to a reduction in endovanilloid dependent TRPV1 activation, and 
reduced lung cell production of cytokines that enhance lung injury, and leading to 
decreased cytotoxicity and GADD153 induction. Results with anandamide, a potential 
endovanilloid involved in LPS-induced lung injury, were less straightforward. 
Anandamide caused GADD153 induction and cytotoxicity, but its effects appeared to be 
primarily TRPV1-independent. Attenuation of lung injury by TRPV1 knockout and LJO-
328 indicates a role for TRPV1 and endovanilloids in lung injury, although the 
mechanism is still ambiguous. Additional work with different endovanilloids may present 
a clearer picture of TRPV1 activation. Additional animal experiments with a more 
relevant model of septic lung injury (such as cecal ligation and puncture), in other 
animals (e.g., rats) or different lung cell or perfused lung models would add to this body 
of work. Immunohistochemical evaluation of TRPV1 and GADD153 co-localization and 
lung microdissection would also better identify specific cellular/regional effects of 




Based on the research presented in this dissertation, key determinants of TRPV1 
activation in human lung epithelial cells include, but are not limited to:  
• Quantity of TRPV1 in the cell 
• Expression of functional TRPV1  
• Subcellular distribution of TRPV1   
• Cell permeability of agonists  
• Agonist concentration 
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• Agonist potency  
• Agonist ability to interact at key TRPV1 binding sites  
• Duration of exposure 
Additional determinants will be identified as TRPV1 is better characterized. 
Figure 1 summarizes the proposed mechanism by which TRPV1 and its agonists affect 
cellular homeostasis, lung physiology, and respiratory function. Briefly, there are two 
separate populations of TRPV1 in parenchymal lung cells and these sub-populations 
mediate immunomodulatory cytokine gene expression (inflammation), GADD153 
induction, ER stress and cell death. In vitro, proinflammatory effects are altered with the 
addition of nonselective, cell impermeable antagonists of TRPV1 such as EGTA or 
ruthenium red, and cell death is not significantly decreased. Use of receptor specific, cell 
permeable TRPV1 antagonists such as LJO-328 attenuates GADD153 induction, ER 
stress, cell death, and cytokine responses. Overall, TRPV1 activation has the potential to 
cause several deleterious outcomes in lung cells that appear to ultimately translate into 
increased recruitment of inflammatory cells to the lung and lung cell damage involving 
apoptosis of lung parenchymal cells.  
Overall, this work defines ER stress as the mechanism of TRPV1 mediated lung 
epithelial cell death, identifies key structural features of nonivamide for TRPV1 
interactions, presents capsaicin analogues as molecular tools to probe TRPV1 function in 




Figure 5.1. Summary diagram highlighting proinflammatory cytotoxic and proapoptotic 
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